METHOD OF CANCER DETECTION

Abstract: Diagnostic/prognostic methods are provided for screening for pathologies wherein an alteration in estrogen metabolism is indicative of a pathology or a susceptibility thereto which comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16OHE1-, 2OHE1- or 2MeoE1- glucuronide fraction, i.e., the fraction which contains the metabolite and its 3-glucuronide conjugate. Methods of preparing reagents to detect said 16OHE1-, 2OHE1-, and 2MeoE1- glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays.

Description: METHODOFCANCERDETECTION FIELD OF INVENTION This invention relates to the medical arts, and more specifically, to the area of diagnostics/prognostics, particularly for oncology, utilizing immunochemical methods. The present invention thus relates to the use of estrogen metabolites, and especially , and 16α-hydroxyestrone (160HE1) as well as conjugates thereof, and assays designed to detect and/or quantify in tissues and body fluids of mammals bearing a tumor burden, abnormal levels of estrogen metabolites and its conjugates. Particularly preferred metabolites for measurement are 20HE1, 2MeoEl, 160HE1 and its glucuronides, and especially, the 20HE1-, 2MeoEl-, and 160HEl-3-glucuronides. BACKGROUND OF THE INVENTION The mechanism for malignancy in mammalian cells has been and continues to be the subject of intense research. One of the most active areas is elucidation of the role of estrogens in the induction and maintenance of malignancies of estrogen-sensitive tissues such as cancers of the breast, endometrium, cervix, and ovary. The clear cut role of estrogens in the induction of breast cancer has led to a long search for evidence of estrogen excess in women with breast cancer. Studies in this area have yielded contradictory results: patients with breast cancer have been reported to have elevated [Hellman L, Zumhoff B, Fishman J, et al. : J Clin Endocrinol Metab 33: 138-144 (1971); Morreal CE, Dao TL, Nemoto T, et al. :J Natl Cancer Inst 63: 1171-1174 ( 1979); Thissjen JH, Poortman J, Schwaπz E: J Ster Biochem 6:729-734 (1975)], normal [Arguelles AE, Poggi UL, Saborida C, et al. : Lancet 1 : 165-168 (1973); Bernstein L, Yuan JM, Ross RK, et al. :Cancer Causes and Control 1 :51-58 (1990)Lor decreased fLemon HM. Wotiz HH, Parsons L, et l. AMA 196: 1128-1136 (1966)) levels of urinary excretion of estrogens. Plasma and serum levels have been reported to be normal [Mancini A, DiPietro C, DeMarinis L, et al.:Gynecol Endocrinol 5: 101-108 (1991); Sherman BM, Wallace RB, Jochimsen PR: Clin Endocrinol 10:287-296 (1979)], or elevated [Bernstein L, Ross RK, Pike MC, et al. :Br J Cancer 61:298-302 (1990); Drafta D, Schindler AE, Milcu SM, et al. J Ster Biochem 13:793-802 (1980)]. The use of antibodies against estrogens for immunohistochemical detection and/or quantitation of estrogens in fresh and fixed tumor tissues has also given controversial results. Kurman et al. in Cancer 42: 1772-1783 (1 78), initially demonstrated localization of estradiol in Sertoli-Leydig tumors of the ovary. Taylor and coworker in Cancer 47:2634-2640 (1981) extended the immunoperoxidase technique to paraffin-embedded tumor tissues taken from women with breast or endometrial cancer, finding that positive staining for estradiol correlated with cytosolic assays for the presence of estrogen receptor. Subsequent research in this area has been reviewed by Taylor [Taylor C, in Bennington, JL (ed), Major Problems in Pathology, Chapter 10, Vol 19, Immunomicroscopy. a diagnostic tool for the surgical pathologist New York, Sanders, 1986, 233-237] While the validity of this method for detecting estrogen receptors has been challenged by Chamness and McGuire in Arch Pathol Lab Med 106 53-54 (1982), all mvestigators agree that an antibody measure of steroid in tissues may be related to endocrine responsiveness or prognosis of a tumor Progress in the immunohistochemistry of steroids in tissues has been limited by the lack of antibodies of appropriately high affinity and, more importantly, by insufficient understanding of the structure of estrogen metabolites as they occur in tissues Previous research has used antibodies that recognize the unconjugated estrogens, not antibodies to conjugated forms of estrogen metabolites as in assays accordmg to this mvention The importance of antibody specificity in immunohistochemical detection and/or quantitation of estrogens in fresh and fixed tumor tissues has not been appreciated prior to this invention No previous researchers have demonstrated 20HE1, 2MeoEl, 160HE1 or its conjugates in normal or tumor tissues by any immunohistochemical method By contrast, there is evidence that malignancies may be associated with disturbances in estrogen metabolism rather than estrogen secretion, and increased 16o -hydroxylation of estradiol does seem to be present in both female animals and men and women with breast cancer The metabolism of estradiol, the ovarian estrogen, is primarily oxidative (FIGURE 1) There is an initial oxidation of estradiol to estrone (I, FIGURE 1) which, in turn, is oxidized mainly by one of two alternative, irreversible pathways, 2- hydroxylation which leads to the relatively nonestrogenic metabolites 2-hydroxyestrone and 2- methoxyestrone (FIGURE 1 , VIII and VII, respectively), and 16o -hydroxylation which leads to the estrogenic metabolite 16α-hydroxyestrone (III, FIGURE 1), among others The relative contribution of the 16α-hydroxvlatιon pathway is relatively constant under most biologic circumstances There are at least two other oxidative pathways for estrogen, 4-hydroxylatιon which leads to 4-hydroxyestrone (40HE1)(IX), and 15a-hydroxylatιon which leads to 15a-hydroxyestrone (150HE1) (X) All of the afore mentioned metabolites, amongst others, (FIGURE 1) may be used by methods of the present invention Alterations may also exist in conjugation of estrogens in tissues and body fluids Research done on urinary estrogen metabolites indicates that urinary estrogens may be covalently conjugated as ethers or esters with glucuronic acids and/or sulphates, respectively, at the steroidal hydroxyl groups Much less is known about the nature of estrogen metabolites in tissues and other bodily fluids Hypothetical conjugates of 160HE1 as they might occur in tissues and/or body fluids are illustrated in FIGURE 2, conjugates of 20HE1 in FIGURE 3, and conjugates of 2MeoEl in FIGURE 4 In 1966, Zumhoff and associates reported that men with breast cancer demonstrated markedh increased 16α -hydroxylation of estradiol [Zumhoff B, Fishman J, Cassouto J, et al J Clin Endocrinol Metab 26 960- (1966)]. These same investigators subsequently reported increased formation and excretion of urinary 16o-hydroxylated estrogen metabolites in women with breast cancer after injection of radiolabelled estradiol [Hellman L, Zumhoff B, Fishman J, et al.:J Clin Endocrinol Metab 33: 138-144 (1971)]. Fishman and colleagues later developed a new isotopic radiometric method that made it possible to measure the relative magnitudes of hydroxylation pathways more readily [Fishman J, Bradlow HL, Schneider J, et al.:Proc Natl Acad Sci USA 77:4957-4960 (1980). This radiometric method involves injection into the animal under study of estradiol labelled with tritium at either the C-2 or C-16 position of the estradiol molecule. Oxidation in vivo at the C-2 and C-16 position frees the tritium from the labeled estrogen, and the radioactive tritium is released as tritiated water. Comparison of the relative amounts of tritiated water (counts per minute) in the serum and/or urine of the injected animal gives an estimate of the relative extent of 2- and 16α-hydroxylation in the animal. Using this radiometric method, Fishman and coworkers greatly extended the study of 16o -hydroxylation and 2-hydroxylation in breast cancer by reporting the following findings: 1) increased 16α-hydroxylation, but unchanged 2-hydroxylation of estrogen was confirmed in women with breast cancer [Schneider J, Kinne D, Fracchia A, et al.:Proc Natl Acad Sci USA 79:3047-3051 (1982)]; 2) increased 16o- hydroxylation was found in women at familial high risk for breast cancer [Bradlow HL, Hershcopf RJ, Martucci C, et al.:Ann NY Acad Sci 464:138-151 (1986)]; and 3) Increased 16α-hydroxylation was found in mouse strains with high incidence of breast cancer, and the degree of increased risk paralleled the increase in 16o -hydroxylation [Bradlow HL, Hershcopf R, Martucci C, et al.:Proc Natl Acad Sci USA 82:6295-6299 (1985). The afore cited radiometric studies found no significant alteration in 2- hydroxylation. This radiometric method is, however, not applicable to routine medical practice, and is complicated by the necessity to normalize the amount of tritium released to the injected animal ' s body volume. Moreover, no information as to the amounts or kinds of estrogens transformed by 16α- hydroxylation of estradiol is obtained by a radiometric method. Recognizing the limitation of the radiometric method, Fishman and co-investigators attempted to develop a radioimmunoassay (RIA) for unconjugated 160HE1 using polyclonal antisera to 160HE1 and tritiated 160HE1 as tracer [Ikegawa S, Lahita R, and Fishman J:J Steroid Biochem 18:329-332 (1983)]. RIAs done upon ethyl ether extracts of serum found very low levels of 160HE1 in serum from normal men and women, averaging only 10 pg/mL in men and 5-16 pg/mL in women. Unfortunately, the researchers found that blank values for water, buffer, and steroid-free serum were also in the range of 5-18 pg/mL. The very low levels of 160HE1 found in this assay, and its lack of reproducibility, obviously precluded its usage in further studies of the role of 16o -hydroxylation in breast cancer, and there are no reports of its use in any further studies. Yoshizawa and Fishman in J Clin Endocr 32:3-6 (1971), also attempted to develop an RIA for unconjugated 20HE1 in methylene chloride extracts of serum. The later RIA found significant differences between clinical groups studied, but this assay was never used in studies of animals with cancer or other proliferative diseases. Emons and coworkers in Acta endocr, Copenh. 91: 158-166 (1979) developed an indirect radioimmunoassay for 2-methoxyestrone in human plasma, but did not apply that assay to studies of estrogen metabolism in disease. These same immunoassays were subsequently used by these investigators, however, in studies of estrogen metabolites in urme. These assays also used the radioimmunoassay method and determmed total urmary 20HE1 and 160HE1 (normalized to urme creatinine concentration) after deconjugation of glucuronides and sulfates with enzyme treatment. For example, Michnovicz et al. in Steroids 52:69-83, 1988, found no significant difference m total urmary 160HE1 secretion when comparing smokers and nonsmokers, but mcreased 2- hydroxylation m smokers; Galbraith and Michnovicz in N. Engl. J. Med 321:269-274, 1989, found no effect of cimetidme on urmary total 160HE1 secretion, but reported a decrease in 2-hydroxylatιon; and, Michnovicz and Galbraith R, m Steroids 55:22-26, 1990, found no effect of thyroxine treatment on total 160HE1 secreted in urme, but mcreased 2-hydroxylatιon with thyroxine treatment. Fmdmg no differences in urinary secretion of an individual urmary metabolite reflective of suspected alterations m estrogen metabolism associated with a specific pathologic condition, Fishman and coworkers developed a method for detecting alterations in estrogen metabolism which comprised isolatmg at least two metabolites of estrone from a biological sample and determining their quotient. This quotient, and/or changes in this quotient, are reported to be reflective of alterations in estrogen metabolism This method forms the basis of European Patent Application No. 0113694.5, filed 17.01.90 by inventors Michnovicz et al. In regard to the utility of measurements of 160HE1, the inventors state in this Application (page 2, line 24-25) that, ". the constitutive nature of this metabolite has discouraged its further consideration for either diagnostic or therapeutic purposes " Moreover, the method of Michnovicz et al. does not recognize the importance of measurmg the glucuronide fractions of the estrogen metabolites, that is, the conjugated forms of metabolites As indicated above, several methods have been used to detect altered estrogen metabolism, especially increased 16o -hydroxylation in animals bearing tumors These methods, however, are not applicable to human research and routine medical practice. Previous attempts to quantify 160HE1 directly by RIA have failed to find measurable levels in serum Therefore, there exists a need the medical art for rapid, accurate, diagnostic tests for metabolites of estrone such as 20HE1 , 2MeoEl , and 160HE1 , assays that reflect altered metabolism and conjugation of estrogens in tissues and bodily fluids from animals The invention disclosed herein meets said need by providing for non-invasive diagnostic/prognostic assays to detect and/or quantify in mammalian tissues and body fluids, preferably serum, estrogen metabolites such as 20HE1 , 2MeoEl , and 160HE1 and their conjugates, preferably the sum of the free metabolite and its 3-glucuronιde conjugate SUMMARY OF THE INVENTION The present mvention involves a method of screening for a pathology in mammals wherem an alteration m estrogen metabolism is mdicative of the pathology or a susceptibility thereto which comprises detecting the level of a particular estrone metabolite and/or its glucuronide fraction from a biological sample taken from the mammal under exammation, and comparmg this level with an extrinsic numerical value derived either previously from the mammal under testmg, or from the testing of other subjects of the same species, to detect any differences in the level of the particular estrone metabolite and its 3-glucuronιde A highly preferred embodiment involves the testing of serum or tissue to measure the level of the 20HE1, 2MeoEl, and 160HE1 glucuromde fraction to detect and/or monitor the growth of tumors in breast cancer The very different conclusions drawn from the prior art and that of the instant invention are due to the followmg distinctions between the prior art and the instant mvention 1) 20HE1, 2MeoEl, and 160HE1 metabolites are not totally deconjugated prior to assay in the present invention, 2) a specific conjugate of 160HE1, substantially, the 20HE1-, 2MeoEl-, and 160HEl-3-glucuronιdes, are measured accordmg to this mvention, not total 20HE1, 2MeoEl, or 160HE1, and 3) the level of the 20HE1-, 2MeoEl-, or 160HEl-3-glucuromde in tissues and/or body fluids is useful by itself, without comparison or indexing to another estrogen metabolites or other substances OBJECTS OF THE INVENTION It is thus an object of the present invention to provide diagnostic/prognostic methods useful for screemng for pathologies wherein an alteration in estrogen metabolism is indicative of a pathology or a susceptibility thereto It is a further object of the present mvention to provide a method for such screening which measures the level of the 160HE1 -glucuromde fraction, l e , the fraction which contains 16α-hydroxyestrone (160HE1) and/or its conjugate, 160HEl-3-glucuronιde It is a further object of the present invention to provide a method for such screening which measures the level of the 20HE1 -glucuronide fraction, l e , the fraction which contains 2-hydroxyestrone (20HE1) and/or its conjugate, 20HEl-3-glucuronιde It is a further object of the present invention to provide a method for such screening which measures the level of the 2 -MeoEl -glucuronide fraction, l e , the fraction which contams 2-methoxyestrone (2-MeoEl) and its conjugate, 2-MeoEl-3-glucuronιde It is a still further object of the present mvention to measure the 160HE1 glucuromde fraction, the 20HEl-glucuronide fraction, or the 2-MeoEl -glucuronide fraction to detect and momtor the growth of tumors, especially tumors in breast cancer. It is yet another object of the present invention to provide for specific diagnostic/prognostic assays to detect and/or quantify the 160H El -glucuronide fraction, the 20HE1 -glucuromde fraction, or the 2- MeoEl -glucuronide fraction in tissues, tissue extracts, and bodily fluids of mammals, and thereby detect tumors, assess their growth, stability, or regression, and provide valuable information for the diagnosis and prognosis of the malignant disease. A still further object of the present invention involves the preparation of test kits which contain the necessary reagents and protocol for the performance of assays which can be used for the aforementioned screemng assays. BRIEF DESCRIPTION OF THE DRAWING FIGURES FIGURE 1 is a chart illustrating the prmcipal oxidative and reductive metabolites of estrone FIGURE 2 is a chart showmg the hypothetical conjugates of 160HE1 as they might occur in tissues and/or body fluids of humans, and other mammals FIGURE 3 is a chart showing the hypothetical conjugates of 20HE1 as they might occur in tissues and/or body fluids of humans, and other mammals FIGURE 4 is a chart showmg the hypothetical conjugates of 2MeoEl as they might occur in tissues and/or body fluids of humans, and other mammals FIGURE 5 is a graph comparing the levels of the 160HE1 -glucuronide fraction in sera of healthy women to those of women with bemgn breast disease and both node-negative and node-positive breast cancer FIGURE 6 is a graph comparmg the levels of the total 160HE1 in sera of healthy women to those of women with both node-negative and node-positive breast cancer FIGURES 7A and 7B are photographs comparmg the breast cancer near adjacent tissue (NAT) with tissue from a normal breast stained for 160H El -glucuronide fraction accordmg to the APAAP direct immunocytochemical assay method of this invention The breast tumor (NAT) tissue (Patient 7893) demonstrates bright red staining surrounding the ductal elements, whereas the normal tissue of similar structure (Patient Co37) is totally unstained Photographs were taken at 845X magnification FIGURE 8 is a graph comparing the levels of the 20HE1 -glucuronide fraction in sera of healthy women to those of women with both node-negative and node-positive breast cancer FIGURES 9A and 9B are photographs comparing the breast cancer tissue with tissue taken from a normal breast stained for 20HE1 -glucuronide fraction according to the APAAP direct immunocytochemical assav method of this invention The breast tumor tissue (Patient 7940) demonstrates purple (red plus blue) staining nuclei of only one apparently normal ductal element within the tumor, whereas the normal tissue of similar structure (Patient Co78) has stamed nuclei withm all of the cells Photographs were taken ar 845X magnification FIGURE 10 is a graph comparing the levels of the 2MeoEl -glucuronide fraction in sera of healthy women to those of women with both node-negative and node-positive breast cancer FIGURE 11 is a graph illustrating the serial monitoring of chemotherapeutic treatment of a 76 year old woman with advanced breast cancer (stage III) with ELISAs for 20HE1-, 2MeoEl-, and 160HE1- glucuromde fractions in serum FIGURE 12 is a graph which further demonstrates the longitudinal momtoring of chemotherapy of a 77 year old woman with metastatic breast cancer (stage IV) with ELISAs for serum 20HE1-, 2MeoEl-, and 160HE1 -glucuromde fractions DESCRIPTION OF THE INVENTION While not wishmg to be bound by any particular theory, it is believed that previous methods to detect and/or quantify estrogen metabolites such as 160HE1, as by immunological assays, have failed because investigators did not recogmze that such metabolites, and especially 20HE1, 2MeoEl, and 160HE1 in tissues and bodily fluids exist predominantly in the form of glucuronides rather than as free, unconjugated species Moreover, it was not known that it is the glucuronide fraction (free plus 3-glucuronιde) that is altered most significantly m animals bearing malignant tumors Further, mvestigators did not recogmze that the physical -chemical nature of the estrone metabolite glucuronide, that is, its negative charge and ability to form Schiff's bases with ammes, promote sequestration of glucuromde in tissues and bodily fluids, chiefly within protem Therefore, immunological assays would not be able to detect and/or quantify the glucuronide fraction in tissues and body fluids unless the assays are done under specific conditions adopted to liberate the tightly bound glucuronide fraction, and high affinity, high specificity antibodies that recognize the glucuronide fraction are used The present invention overcomes the limitations of the prior art by utilizing in the practice of this mvention antibodies which recogmze epitopes on both the free estrone metabolite and its 3 glucuronide conjugate equivalently, thus providing assays that are able to simultaneously detect and/or quantify both the unconjugated and 3-glucuronιde forms of the estrone metabolite The novel buffer compositions, monoclonal antibodies, and assav methods taught herein enable nearly complete recovery of sequestered 20HE1 , 2MeoEl, 160HE1 and their respective 3-glucuronιdes from tissues and bodily fluids with antibodies of this invention Other metabolites which can similarly be utilized include but are not limited to 2-hvdroxyestrone 4 -hvdroxy estrone, 15α-hydroxy estrone, 16α-hydroxyestrone, 2-methoxyestrone estnol, 17β-estπol, epiestπol, 16-ketoestradιol, estradiol, 15α-hydroxvestradιol, 2-hydroxyestradιol 2 hydroxyestπol, 2-methoxy estradiol, 2-methoxyestπol, and 4-methoxyestradιol The Examples section illustrates the use of the 20HE1-, 2MeoEl , and 160HE1 glucuronide fractions in screening methods for use as mmor markers and tumor-associated antigens The diagnostic/prognostic methods illustrated herein can be used for the detection of neoplastic disease . Also provided are compositions and test kits for implementing such methods. The discovery that said estrone metabolite glucuronide fraction is altered in human tissues and serum of cancer patients has opened the way for the development of novel methods and compositions for the diagnosis and treatment of malignant disease in humans and other mammals. The assays of this invention are both diagnostic and/or prognostic. The term "diagnostic/prognostic" is herein defined to encompass the following processes depending upon die clinical context: determining the presence, extent, and nature of the disease; differentiating benign from malignant disease; predicting the most likely course and outcome of the disease; monitoring a patient for recurrence of disease; and, determining the preferred type and timing of therapy for a patient with cancer. In a highly preferred embodiment of the invention, the screening method disclosed herein utilizes the detection of 160HE1 and its conjugates at elevated levels in tissues and in bodily fluids of mammals to determine which carry a malignant tumor. The elevated portion of 160HE1 in serum comprises substantially 160HEl-3-glucuronide and 160HE1, termed the "160HE1 -glucuronide fraction", and the detection and measurement of this fraction provides highly useful methods for detecting the presence and extent of tumors in neoplastic disease, particularly in breast cancer. Similarly, in a highly preferred embodiment, the screening method disclosed herein utilizes the detection of 20HE1 glucuronide fraction and/or 2MeoEl glucuronide fraction at relatively high, moderate, or low levels in tissues and body fluids of mammals bearing a tumor burden, or to predict the liklehood of tumor regression, stability, or progression of an estrogen-sensitive neoplastic disease, particularly in breast cancer. Methods and compositions are provided for detecting and/or quantifying said 20HE1-, 2MeoEl-, and 160HE1 -glucuronide fractions in tissues and bodily fluids. Further, diagnostic/ prognostic methods are provided wherein other conjugated fractions of 20HE1, 2MeoEl, and 160HE1 are found in mammalian bodily fluids. For example, specific glycolytic and/or arylsulpholytic enzymes may be used to convert conjugates of 160HE1 including 160HEl-3,16-glucuronide, 160HEl-16-glucuronide, 160HE1-3- sulphate, and 160HEl-3-sulphate-16-glucuronide to unconjugated 160HE1 or 160HEl-3-glucuronide for assay in the described immunoassays of this invention. "Substantially" as used in the context of the "glucuronide fraction" indicates that although the estrone metabolite and its glucuronide and sulphate conjugates are elevated in malignant tissues, the significant, variable fraction of conjugated estrone metabolites in tissues and body fluids of mammals bearing malignant tumors exists as the 3-glucuronide. It can be appreciated that an estrogen within the bodily fluids would be subject to a variety of metabolic processes, including glucuronidation and sulphation, among others Further, it can be appreciated that cells withm tissues under the influence of neoplastic processes might conjugate estrogens differently than cells withm normal healthy tissues Thus, by way of illustration, not limitation, the " 160HE1 -glucuromde fraction" would encompass 160HE1 and 160HE1- 3-glucuronιdes, as well as 160HE1 conjugated at the 3-posιtιon with chemical moieties other than glucuronides (FIGURE 2) Assays accordmg to the present invention would detect and/or quantify 3- substituted 160HE1, if the 3-substιtuent were a small sugar, an ammo acid, or other neutral or charged compound The said 160HE1 -glucuromde fraction mcludes unconjugated 160HE1 because a portion of 160HE 1-3 -glucuronides may be converted to 160HE1 by hydrolysis during isolation and/or processmg of tissues or body fluids, as by endogenous β-glucuronidases or chemical treatments Representative methods and compositions accordmg to this invention include those for identifymg patients who have a pathology associated with an alteration in estrogen metabolism, especially a neoplastic disease, and most especially, malignant tumors An exemplary method comprises the steps of detecting the level of the said 160HE1 -glucuromde fraction as described herein in a sample of patient's tissue or bodily fluid, and determining whether that level is elevated above normal As shown herein, malignant tumors and tissues adjacent to malignant tumors release higher levels of said 160HE1 -glucuromde fraction into bodily fluids than do bemgn tumors or normal tissues Thus, a higher level than normal level of said 160HE1 -glucuromde fraction is mdicative of the presence of one or more malignant tumors Conversely, due to the metabolic processes by which they are derived, and their antiestrogenic activities, an altered level of the 20HE1- or 2MeoEl -glucuronide fraction in tissues and body fluids of a mammal bearmg a tumor burden , or suspected of bearmg a tumor, may be indicative of the presence of one or more malignant tumors, or be prognostic for progression or regression of an estrogen-sensitive malignancy, especially breast cancer In the practice of this invention the animal tested is preferably human, and the bodily fluid tested is preferably serum An important parameter of the status and likely outcome of the patient with gynecologic cancer can be determined by testing a body fluid, preferably serum, from the patient for elevated 160H El -glucuronide fraction Exemplary means of detecting and/or quantifying said 160HE1- glucuronide fraction, whether in mammalian body fluids, tissues or tissue extracts, include ligand binding assays, and immunoassays among other means Immunoassays are the preferred means of detecting the 20HE1-, 2MeoEl , or 160HE1 -glucuronide fractions, most preferably, a competitive inhibition immunoassay In such an immunoassay format, antibodies specific to said 160H El -glucuronide fraction, 2MeoEl -glucuronide fraction, or 20HE1 glucuronide fraction can be used with their paired respective 160HE1 -labeled, 2MeoEl -labeled, or 20HE1 -labeled enzymes, radioisotopes, fluorescent, or chemiluminescent tracers to compete with estrogen metabolite for bmdmg to antibodies Such antibodies can be prepared by methods known in the art, and described, for instance, m Klug et al , Steroids, Vol 59, pp 648-655 (1994) An important parameter of the status and likely outcome of the patient with gynecologic cancer can be determmed by testmg tissue, preferably fresh or formalin-fixed paraffin-embedded tissue sections Exemplary means of detecting and/or quantifying said 20HE1- or 160HE1 -glucuronide fraction in tissues mclude immunohistochemical detection, preferably with the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method Further, assay results obtamed accordmg to the practice of this invention indicating the presence of abnormal levels of glucuromde fraction in body fluids or tissues of humans can be used in conjunction with results of other assays of neoplastic disease, such as, for example, estrogen receptor (ER) and progesterone receptor (PR) assays, to provide useful prognostic and diagnostic information Still further, the assays of this mvention are useful for detection of malignant disease both pre- and post- operatively For example, patients displaying elevated levels of said 160H El -glucuronide fraction in early stages of disease may be treated more aggressively, thus affordmg the patient a chance of increased survival By contrast, patients with early stage tumors, or even relatively advanced tumors with low, normal, or slightly elevated 160HEl-glucuromde fraction may be treated more conservatively, thus avoiding chemotherapeutic trauma and excess costs Similarly, increases or decreases in said 160HE1- glucuromde fraction during therapy may correlate with, and corroborate, objective evidence of the patient s response to therapy The levels of 20HE1- and/or 2MeoEl -glucuronide fraction can be similarly utilized The assays of this invention can also be used to predict the likely existence of lymphatic involvement (nodal status) and/or metastatic spreads of malignant disease For example, patients displaying very elevated levels of said 160H El -glucuromde fraction and low levels of 20HE1 and/or 2MeoEl- glucuronide fraction, may be considered to have, or be at increased risk, of lymphatic involvement and metastatic spread of disease This information may be used in conjunction with other available information to more accurately stage the cancer, and decide upon the course and timing of treatment The assays of this invention which indicate the presence of said glucuronide fraction in body fluids of humans are useful to detect and diagnose cancer, including screening of populations for cancer, preferably when used adjunctively with other screening methods such as mammography and cervical PAP testing The mvention also provides for test kits useful for the practice of the assays of the mvention wherein said test kits comprise antibodies reactive with 20HE1, 2MeoEl, 160HE1 and/or said 20HE1-, 2MeoEl-, and 160HE1- glucuromde fractions, enzymes, radioisotopes, fluorescers, or chemiluminescers as detection elements, m combination with contamers, pipettes, slides, plate, coated well, etc , typically utilized m such test kits The assays can be solid phase assays, but are not limited thereto, and can be m a liquid phase format, and can be based on enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays, fluorometric assays, chemiluminescent assays, and particle agglutination assays, all of which may be amplified or unamplified through methods known in the diagnostic arts The concept underlying this mvention is the discovery that patients suffering from a pathology associated with an alteration in estrogen metabolism have m their bodily fluids abnormal levels of metabolites of estrone, and the altered fraction of estrone metabolites associated with the pathology is, in a preferred embodiment, substantially the sum of the metabolιte-3-glucuromde and unconjugated metabolite, herein designated the "glucuronide fraction" The said glucuronide fraction may thus be utilized as a novel tumor marker and tumor-associated antigen Assays for Glucuronide Fraction Mammalian Tissues and Bodv Fluids Non-invasive diagnostic/prognostic assays are provided to detect and/or quantify said glucuronide fraction m body fluids of mammals, preferably humans It can be appreciated that metabolites of estrone may be present in a patient's tissues and body fluids as, in the case of 160HE1, unconjugated metabolite, metabolιte-3-glucuronιde, metabolιte-3, 16-glucuronιde, metabolιte-16-glucuronιde, metabolιte-3-sulfate, or metabolιte-3-sulfate,16-glucuromde conjugates, among others (see FIGURE 2) Said conjugates mav be detected and/or quantified by the assays of this invention if they contain epitopes recognized by the antibodies of this invention Certain conjugates of estrone metabolites may require pretreatment with enzymes prior to assay to remove conjugated groups that obscure the epitopes recognized by the antibodies of this invention For example, treatment of 160HEl-3,16-glucuronιde with the enzyme β- glucuromdase, preferably enzyme derived from E Colt, will reduce the former conjugate to 160HE1 or 160HEl-3-glucuronιde, both recognized equally by antibodies of this invention Treatment of 160HE1- 3-sulfate with the enzyme arylsulfatase, preferably that derived from the snail, Helix Pomatta, will reduce the former conjugate to 160HE1, an estrogen recognized by antibodies of the present invention Treatment of the mixed conjugate 160HEl-3-sulfate, 16-glucuronιde with a mixture of the enzymes β- glucuronidase and arylsulfatase described, will reduce the former 160HE1 conjugate to 160HE1 The exact use of these same enzymes with conjugates of 20HE1 and 2MeoEl (FIGURES 3 and 4) to obtain unconjugated and partially conjugated forms of 20HE1 and 2MeoEl is obvious to those skilled in the art The body fluids that are of particular interest in assaying for said glucuronide fraction according to methods of this invention include blood, serum, plasma, urine, breast exudate, saliva, sputum, cytosols, ascites, pleural effusions, and cerebrospinal fluid. Blood, serum, and plasma are preferred, and serum is the most preferred body fluid according to methods of this invention. The assays of this invention can also be used to detect and/or quantify the glucuronide fraction in tissues. Tissue preparations of particular interest include fresh tissue sections, fixed paraffin-embedded tissue sections, cell smears, cell suspensions, or freeze-mounted cells, preferably formalin-fixed paraffin-embedded tissue sections. From a knowledge of the conjugates associated with malignant diseases, said glucuronide fraction as disclosed in this invention, monoclonal or polyclonal antibodies can be generated that specifically recognize said glucuronide fraction, that is, 160HE1 and 160HEl-3-glucuronide, 20HE1 and 20HE1-3- glucuronide, and 2MeoEl and 2MeoEl-3-glucuronide. Because the said glucuronide fraction is found to be tightly bound to proteins, said fraction is not ordinarily found to exist freely in the tissues and body fluids of mammals. By methods revealed in this invention, however, said glucuronide fraction may be sufficiently liberated for binding by antibodies of this invention making detection and/or quantification possible. Utilizing current immunodiagnostic techniques that can quantify the binding of said glucuronide fraction to monoclonal antibodies of this invention, one can determine the amount of said 160HE1- glucuronide fraction in tissues and body fluids of cancer patients. Representative immunoassays involve the use of monoclonal antibodies and estrone metabolite-enzyme conjugates in competitive enzyme-linked immunoassays (ELISAs). A preferred method to generate monoclonal antibodies involves covalently linking a metabolite, such as 20HE1, 2MeoEl, or 160HE1, to a protein and using it as an immunogen. Still further, the metabolite - glucuronide, such as 20HE1-, 2MeoEl-, or 160HEl-3-glucuronide, can be covalently linked to protein and be used as antigen. By this method, many monoclonal antibodies recognizing and binding different conjugates of 160HE1 or other estrone metabolites can be generated and selected, and such antibodies could be used to detect or identify differently conjugated fractions of 160HE1 or other metabolites of estrone. The monoclonal antibodies of this invention were generated in mice after immunization with 20HE1 , 2MeoEl, or 160HE1 covalently linked to keyhole limpet hemocyanin (KLH), and individual antibodies were selected to recognize and bind both the unconjugated metabolite and its respective-3- glucuronide with high affinity and specificity. The diagnostic/prognostic assays with monoclonal antibodies according to this invention would typicall involve obtaining a small amount of body fluid, preferably serum, from the mammalian host. The presence of the particular metabolite glucuronide fraction in serum can then be detected and/or quantified by a variety of immunodiagnostic techniques, including ELISA, RIA, and fluorescent, chemiluminescent assays, among others. For example, a representative of one type of ELISA test is a format wherein a microtiter plate is coated with, for example, monoclonal antibody to 160HEl/160HEl-3-glucuromde, and to said microtiter plate is added an appropriately treated sample of patient serum mixed with an enzyme covalently labeled with 160HE1 After a period of mcubation permitting competition between 160HE1 -enzyme and serum 160HE1 -glucuromde fraction for bindmg to monoclonal antibody bound to the solid phase, the plate is washed, and a color-generating enzyme substrate is added to determme the amount of 160HEl-enzyme bound The quantity of 160HE1 -glucuronide fraction in each serum sample is determmed from the absorbance of the sample relative to a set of 160H El -glucuronide standards and controls of known concentration The amount of inhibition of absorbance is directly proportional to the concentration of said 160H El -glucuromde fraction in each serum sample It is apparent to one skilled in the art of diagnostic/prognostic assays that a wide variety of immunological assay methods are available for measurmg the formation of antigen antibody complexes Numerous formats and protocols for immunodiagnostic assays are described the scientific and patent literature Exemplary immunoassays which are especially suitable for detectmg a serum antigen mclude those described in U S Patent 3,654,090, 3,850,752, RE 31,006 and 4,016,043 Antibodies employed in assays may be labeled or unlabeled Suitable detection means mclude the use of labels such as enzymes, radioisotopes, fluorescers, chemiluminescers, particles, dyes, and the like. Such labeled reagents may be used in a variety of well known assay formats See, for example, U S Patent Nos 3,654,090, 3,850,752 and 4,016,043 The assays of the present invention are useful for screemng for a wide vaπety of neoplastic diseases wherein an elevation or change in estrogen metabolism is indicative of disease or a susceptibility thereto Exemplary neoplastic diseases include carcinomas, such as adenocarcinomas, melanomas, squamous cell carcinomas, mesodermal tumors, sarcomas, leukemias, and lymphomas Of particular interest are gynecological cancers including ovarian, cervical, vaginal, endometrial, prostate and breast cancer Tumors of tissues which are known to express estrogen receptors (ER) are good candidates for neoplastic diseases for use of assays of this invention As outlined in the Background above, increased 16α- hydroxylation has been associated with breast, cervical, and endometrial cancer mammals, and, therefore, the assays of this mvention are especially useful in the screenmg for and monitoring of these cancers Competitive Direct Enzyme-linked Immunoassay A preferred assay format for the glucuronide fraction according to this invention is the competitive enzyme-linked immunoassay Briefly, the concentration of the glucuronide fraction is determined by competitive binding between the glucuromde fraction in body fluids and metabolite-labeled enzyme for antibody to glucuronide fraction bound to a microtiter plate Antibody bound to the solid phase provides a capture system for said glucuronide fraction, estrone metabolite-labeled enzyme Higher concentrations of said glucuronide fraction in solution competitively inhibits binding of metabolite-labeled enzyme, and after equilibrium is reached, the amount of enzyme captured by antibody on the solid phase is determined by adding a colorless enzyme substrate which becomes colored after reacting with enzyme on the solid phase. The amount of glucuronide fraction is determined by reference to standards containing known amounts of the metabolite-3-glucuronide. A further competitive ELISA according to this invention reverses the orientation of antigen and antibody in the assay, wherein glucuronide fraction covalently coupled to protein is bound to the solid phase and antibody to said glucuronide fraction is labeled with enzymes. There are many different embodiments of the competitive inhibition ELISA. For example. In a prefeπed format for 20JHE1, 2MeoEl, or 160HE1 glucuronide fractions, rabbit antibody to mouse IgG, Fc- fragment specific (Jackson ImmunoResearch, Avondale, PA, USA) is passively coated to the wells of a polystyrene microtiter plate (Maxisorb 8 X 12 plate, NUNC, Napierville, IL, USA), wherein the coating volume is 150 uL/Ml, and the antibody concentration is 2 ug/Ml in PBS. In such a preferred assay, bodily fluid diluted in an appropriate buffer is mixed in solution with a monoclonal antibody to said 160HE1 -glucuronide fraction, preferably the monoclonal antibody clone 19H7 (described below), and 160HE1 -labeled enzyme, preferably 160HEl-alkaline phosphatase (AP, Sigma Chemical Co., St. Louis, MO, USA). It is preferred that there be 5-10 ng/mL of monoclonal antibody, and 0.5-1 U/mL of 160HE1 -labeled AP in a reaction volume of 150 uL. It is preferred that body fluid, preferably serum be diluted 1 :4 to 1 :20 in the assays of this invention. It is preferred that 160HE1 derivatives for conjugation to enzymes and odier proteins be synthesized as described by Ikegawa and Fishman, Steroids, 39:557-567, 1982, and be linked to enzyme, preferably AP, following Mattox, Litwiller, and Nelson in J. Steroid Biochem. 10:167-172, 1979. A preferred method for preparing estrone metabolite-3-glucuronide and estrone metabolite-3-glucuronide-labeled enzymes and proteins for use according to this invention is isolation from late pregnancy urine and conjugation to enzymes and proteins as described by Samarajeewa, Leepipatpaiboon, and Coulson, Steroids 36:611-618, 1980. Preferred hydrogen ion buffers for assays of this invention are those commonly known as "Good" buffers as described by Good et al. in Biochemistry 5: 467-477, 1966, and in Analytical Biochemistry 104:300- 310, 1980. These buffers are typically zwitterionic amino acids, either N-substituted taurines or N- substituted glycines, and are preferred because these compounds assist in disrupting the interactions between the said glucuronide fraction and proteins in tissues and body fluids. These buffer salts achieve this effect through ion-pair formation with the negatively charged glucuronides, and by their amphiphilic nature, promote the base catalyzed hydrolysis of Schiff's bases between said lόOHEl-glucuronide fraction and primary amino groups on proteins. Further, it is preferred that the buffers of assays of this invention be kept acidic (pH < 7,0) to protonate said 160HE1 -glucuronide fraction, thereby minimizing charge interactions with proteins in tissues and body fluids Assays described in this invention utilize the Good buffer 2-(N-Morphohno) ethanesulfonic acid (MES) It is further preferred that assays of this mvention be performed at temperatures below 15 deg Centπgrade Example 1 below provides the details of a preferred protocol for a competitive direct ELISA to detect and/or quantify the said 160HE1 -glucuronide fraction in serum according to this invention Further, Example 2 below provides details of a protocol to detect and/or quantify total serum 160HE1- glucuromdes Example 4 below provides the details of a preferred protocol for a competitive ELISA to detect and/or quantify the said 20HE1 -glucuromde fraction in serum accordmg to this invention Example 6 below provides the details of a preferred protocol for a competitive ELISA to detectO and/or quantify the said 2MeoEl -glucuromde fraction in serum according to this invention Immunocytochemical assays A preferred assay method for the detection and/or quantification of said glucuronide fraction in tissues according to this mvention is the lmmunoenzymatic labeling procedure utilizing the "unlabeled antibody bridge", preferably the alkaline phosphatase anti-alkaline phosphatase (APAAP) technique, and fixed tissue sections, preferably formalin-fixed paraffin-embedded tissue sections In this method, prepared glass slide mounted tissue sections are incubated sequentially with 1 ) mouse monoclonal antibody to said glucuronide fraction, 2) rabbit polyclonal anti-mouse IgG antiserum, and 3) mouse anti-alkaline phosphatase alkaline phosphatase immune complexes (APAAP) The rabbit anti-mouse IgG acts to bridge the primary monoclonal antibody the APAAP complex, linking the two together The presence of tissue-bound APAAP, and hence tissue-bound antibody to the said glucuromde fraction, is visualized b\ incubation of the treated tissue with a color producmg substrate for alkaline phosphatase, preferably napthol AS-MX as coupling reagent and Fast Red as capture agent yielding a bright red color There are many different embodiments of the lmmunoenzymatic "unlabeled antibody bridge' technique including those using the peroxidase anti-peroxidase (PAP) technique In a preferred format for said glucuronide fraction, glass slide mounted formalin-fixed paraffin-embedded sections, preferably 4 to 10 um thick, are deparaffinized with n-decane, rehydrated, and incubated with monoclonal antibody to said glucuronide fraction in TBS The tissue is washed extensively with TBS incubated for 1 hour with rabbit antibody to mouse IgG, is washed with TBS, and incubated with APAAP complex for 30 min After a final wash with TBS, bound primary monoclonal antibody to said 160HE1 glucuronide fraction is detected and/or quantified by incubating with a mixture of napthol AS-MX and Fast Red in diethanolamine buffer, pH 8 9, for about 10 minutes, or until intense red color is produced Levamisole (5 mM) is mcluded in the substrate buffer to inhibit endogenous alkaline phosphatase activity m tissues Commercial APAAP kits contaimng reagents for use with murine monoclonal antibodies are available for the described procedure, preferably that manufacmred by DAKO Coφoration, Carpenteπa, CA, USA (Product No 670K). The concentrations of all reagents are adjusted to optimize development of specific staining, while keepmg non-specific background staining to a mmimum General techniques and principles of lmmunolabeling of monoclonal antibodies by the APAAP technique are discussed further by Mason m Techmques in Immunocytochemistry. Vol 3, pp 25-42, Bullock and Petrusz, eds , Academic Press, 1985 Example 3 below provides details of a preferred protocol for an immunocytochemical lmmunoenzymatic APAAP assay for said 160HE1 -glucuronide fraction accordmg to this invention Example 5 below provides details of a preferred protocol for immunocytochemistry of 20HE1 -glucuromde fraction tissues Test Kit. The above assay accordmg to this mvention can be embodied in test kits to detect and/or quantify the estrogen metabohte-glucuromde fraction in mammalian, preferably human, tissues and body fluids wherem such test kits comprise antibodies, monoclonal and/or polyclonal, that can recogmze epitopes on the estrogen metabohte-glucuromde fraction. Such diagnostic/ prognostic kits, for instance in the case of 160HE1, can further comprise, alone or m combmation with the aforementioned antibodies to said 160HE1 -glucuromde fraction, labeled 160HE1 and/or labeled 160HEl-3-glucuromde, 160HE1 and/or 160HEl-3-glucuronιde standards dispersed m tissues or body fluids, as well as positive and/or negative controls, and other reagents as necessary to perform the assays according to this invention Example 7 below provides a detailed description of one such test kit for the measurement of the 160HE1- glucuromde fraction in human serum Example 8 below provides a detailed description of one such test kit for the measurement of the 160H El -glucuronide fraction in human tissues It is obvious to those skilled in the art, given the Examples, that similar kits for 20HE1 and 2MeoEl glucuronide fraction may be readily constructed Preparation of Monoclonal Antibodies Monoclonal antibodies useful in this invention are obtained by the well-established process of cell fusion as described by Milstein and Kohler in Nature 256 495-497, 1975, and, more preferably, for antibodies to said 160HE1 -glucuronide fraction and 160HEl-3-glucuronιde for assays according to this mvention, as described by Lane, Cπssman, and Gmn m Methods of Enzymology 121 183-192, 1986 MAhs 12C2. 12D7. 16F11. and 19H7 to 16QHE1 -glucuromde Fraction All monoclonal antibodies were made by fusing splenocytes from female Balb/C mice immunized with 160HE1-KLH estroge protein conjugates with non-immunoglobulin secreting murine myeloma cell lme SP2/0-AG14 (ATCC CRL1581). It is prefeπed that 160HE1 derivatives for conjugation to enzymes and other proteins be synthesized as described by Ikegawa and Fishman in Steroids 39:557-567, 1982, and be linked to protein following Mattox, Litwiller, and Nelson in J. Steroid Biochem. 10: 167-172, 1979. A prefeπed method for preparing 160HEl-3-glucuronide and 160HEl-3-glucuromde-labeled enzymes and proteins for use accordmg to this invention is isolation from late pregnancy urine and conjugation to enzymes and protems as described by Samarajeewa, Leepipatpaiboon, and Coulson in Steroids 36:611- 618, 1980. Six 10-14 week old female Balb/C mice were immunized i.p. with 50-100 ug of 160HE1-KLH conjugate in 0.5 mnL of TiterMax adjuvant (CytRx Corporation, Norcross GA, USA) in PBS (50:50 v/v). Animals were boosted i.p. with 50-100 ug of emulsified antigen in TiterMax at monthly intervals for three months, or until mice demonstrated antibody to conjugate. Mice were bled and tested for antibody to 160HEl/160HEl-3-glucuronιde every two weeks in an ELISA (described below). Mice with highest titers were injected intravenously with 100 ug of 160HE1-KLH in sterile salme via the tail vein 4 days prior to cell fusion. Splenocytes from boosted mice were fused with SP2/0-AG14 mouse myeloma fusion partner cells usmg the high efficiency fusion protocol described by Lane, Crissman, and Ginn (see reference above). Spleen cells at 5: 1 ratio with SP2/0 cells were fused with 30% polyethylene glycol 1000, and distributed in 0.13 mL aliquots into twenty-five 96-well culture plates at 4 X IO 4 cell per well in media contaimng Hybridoma Enhancing Medium (HEM, Sigma Chemical Company, St. Louis, MO USA). A super-rich growth medium consisting of HY medium (90% DMEM, high glucose, 10% NCTC 135), 20% fetal bov e serum, 4 Mm L-glutamine, 20% HEM, and 30 ug.Ml carboxyethyl gama-amino butyric acid (GABA) was used for feed g and subcloning. Selection for hybridoma cells was with hypoxanthine and azaseπne. Each well was tested for antibody to 160HEl/160HEl-3-glucuronιde when it became confluent with hybrid cells. All of the wells were tested over a three week period, and positive hydπds were cloned twice by limiting dilution in super rich medium without azaser e. The presence of antibodies to 160HE1 -glucuronide fraction and/or 160HEl-3-glucuronιde was determined by a specific ELISA. Microtiter plates were coated 16 hours with rabbit anti-mouse IgG in PBS. The plates were blocked with 1 % BSA in PBS for 1 hour, and after washing, culture supernatants (100 uL/well) were added to the plates and incubated for 2 hours. Plates were washed, and 160HE1- alka ne phosphatase (300 U/mL) diluted 1 :2000 with 0.1 % gelatin in PBS was added. After a 1 hour incubation, plates were washed with PBS containing 0.05% Tween-20, and enzyme substrate, 3.8 mM paranurophenylphosphate in IM diethanolamine with 1 mM MgCl 2 , pH 9.8 was added The presence of antibody to 160HE1 -glucuromde fraction was seen by the development of a yellow color read at 405 nm m a microtiter plate reader The isotopes of monoclonal antibodies were determined similarly, except that rabbit anti-mouse IgG heavychain- and/or light chain-specific antibody alkaline phosphatase conjugates were used (Zymed, San Francisco, CA USA) Mah 4C11 to 2QHE1 -Glucuronide Fraction All monoclonal antibodies were made by fusmg splenocytes from female Balb/C mice immumzed with 2- Hydroxyestrone (20HE1)-KLH estrogen protem conjugates with non-immunoglobulin secreting murine myeloma cell lme SP2/0-AG14 (ATCC CRL1581) It is preferred that 20HE1 derivatives for conjugation to enzymes and other proteins be synthesized as described by Ball et al in Steroids 31 249- 258, 1978 and be linked to protem followmg Mattox, Litwiller, and Nelson in J Steroid Biochem 10 167- 172, 1979 Followmg these methods, the 20HE1 derivatives are made as the 17-carboxymethyloxιme and linked to proteins through the C-17 position of 20HE1 A prefeπed method for preparing 20HE1-3- glucuromde and 20HEl-3-glucuronιde-labeled enzymes and proteins for use accordmg to this invention is isolation from late pregnancy urine and conjugation to enzymes and proteins as described by Samarajeewa, Leepipatpaiboon, and Coulson in Steroids 36 611-618, 1980 Six 10-14 week old female Balb/C mice were immumzed I p with 50-100 ug of 20HEE1-KLH conjugate m 0 5 mL of TiterMax adjuvant (CytRx Corporation, Norcross GA, USA) PBS (50 50 v/v) Animals were boosted l p with 50-100 ug of emulsified antigen in TiterMax at monthly intervals for three months, or until mice demonstrated antibody to conjugate Mice were bled and tested for antibody to 20HE1 every two weeks m an ELISA similar to that used for antibodies to 2MeoEl (described below) Mice with highest titers were jected intravenously with 100 ug of 20HE1-KLH in sterile sal e via the tail vein 4 days prior to cell fusion Spleen cells at 5 1 ratio with SP2/0 cells were fused with 30% polyethylene glycol 1000, and distributed in 0 2 mL aliquots into ten 96-well culture plates at 2 X 10 cell per well media contammg Hybridoma Enhancing Medium (HEM, Sigma Chemical Company, St Louis, MO USA) The growth media consisted of RPMI 1640, 10% heat-inactivated fetal bovine serum, 0 1 mM MEM nonessential ammo acids, 2 mM glutamine, and HAT hypothanxine/aminopteπn/ thymidine, 100 0 4 16 X 10 6 M) After a majority of the hybridomas had grown to confluence (about 10-14 days), all 960 wells were screened simultaneously for antibodies to 20HE1 The presence of antibodies to 20HE1 and/or 20HE1 -glucuronide fraction was determined by a specific ELISA as described above for antibodies to 160HE1 using 20HEl-17-lιnked alkaline phosphatase The isotypes of monoclonal antibodies were determmed similarly, except that rabbit anti-mouse IgG heavy chain and/or light chain-specific antibody alkaline phosphatase conjugates were used (Zymed, San Francisco, CA USA) MAb 9D3 to 2MeoEl -Glucuronide Fraction All monoclonal antibodies were made by fusing splenocytes from female Balb/C mice immunized with 2- Methoxyestrone (2MeoEl)-KLH estrogemprotein conjugates with non-immunoglobulin secreting murine myeloma cell line SP2/0-AG14 (ATCC CRL1581). It is preferred that 2MeoEl derivatives for conjugation to enzymes and other proteins be synthesized as described by Ball et al. in Steroids 31:249- 258, 1978 and be linked to protein following Mattox, Litwiller, and Nelson in J Steroid Biochem 10: 167- 172, 1979. Following these methods, me 2MeoEl derivatives are made as the 17-carboxymethyloxime and linked to proteins through the C-17 position of 2MeoEl. A preferred method for preparing 2MeoEl- 3-glucuronide and 2MeoEl-3-glucuronide-labeled enzymes and proteins for use according to this invention is isolation from late pregnancy urine and conjugation to enzymes and proteins as described by Samarajeewa, Leepipatpaiboon, and Coulson in Steroids 36:611-618, 1980. Six 10-14 week old female Balb/C mice were immunized i.p. with 50-100 ug of 2MeoEl-KLH conjugate in 0.5 mL of TiterMax adjuvant (CytRx Coφoration, Norcross GA, USA) in PBS (50:50 v/v). Animals were boosted i.p. with 50-100 ug of emulsified antigen in TiterMax at monthly intervals for three months, or until mice demonstrated antibody to conjugate. Mice were bled and tested for antibody to 2MeoEl every two weeks in an ELISA similar to that used for antibodies to 2MeoEl (described above). Mice with highest titers were injected intravenously with 100 ug of 2MeoEl-KLH in sterile saline via the tail vein 4 days prior to cell fusion. Spleen cells at 5:1 ratio with SP2/0 cells were fused with 30% polyethylene glycol 1000, and distributed in 0.2 mL aliquots into ten 96-well culture plates at 2 X 10" cell per well in media containing Hybridoma Enhancing Medium (HEM, Sigma Chemical Company, St. Louis, MO USA). The growth media consisted of RPMI 1640, 10% heat-inactivated fetal bovine serum, 0.1 mM MEM nonessential amino acids, 2 mM glutamine, and HAT (hypothanxine/aminopterin/thymidine; 100:0.4: 16 X IO "6 M). After a majority of the hybridomas had grown to confluence (about 10-14 days), all 960 wells were screened simultaneously for antibodies to 2MeoEl . The presence of antibodies to 2MeoEl and/or 2MeoEl -glucuronide fraction was determined by a specific ELISA as described above for antibodies to 160HE1 using 2MeoEl-17-linked alkaline phosphatase. The isotypes of monoclonal antibodies were determined similarly, except that rabbit anti-mouse IgG heavy chain and/or light chain-specific antibody: alkaline phosphatase conjugates were used (Zymed, San Francisco, C A USA). Characterization of Monoclonal Antibodies All cell lines which bound lόOHEl-alkaline phosphatase underwent at least two subclonings by limiting dilution to insure monoclonality prior to characterization. Specificities of antibodies to 160HE1 metabolites were determme by a competitive inhibition ELISA, but with decreasing concentrations of (10 to 0 ug/mL) of the estrogen, androgen, or non-steroidal compound to be tested for cross-reactivity. The specificity of each monoclonal antibody for its antigen was defined as per cent cross-reactivity, and reflects the relative affinities of the antibody for different antigens Cross-reactivity was defined as the ratio of concentrations of tested compounds to concentration of 160HE1 required to give 50% inhibition of 160HE1 -labeled enzyme binding in the competitive ELISA, times 100 Monoclonal antibodies to 160HE1 were tested for specificity against 160HE1 conjugates and against structurally related estrogen and androgen metabolites, particularly against 16o-hydroxylated steroids Monoclonal antibodies for use m the present invention were selected to react nearly equivalently with 160HE1 and 3-substιtuted 160HE1, that is to react with said 160HE1 -glucuronide fraction Not all monoclonal antibodies to 160HE1 generated as described above demonstrated specific reactivity with the said 160HE1 -glucuromde fraction The relative affmities of monoclonal antibodies to 160HE1 metabolites were determined by domg the competitive inhibition ELISA with decreasmg amounts of 160HE1 (1000 to 0 pg/mL) in the presence of a fixed amount of 160H El -alkaline phosphatase and monoclonal antibody in the wells of a microtiter plate (see Competitive Direct Enzyme-linked Immunoassay, above) Affmities were estimated assummg that the concentration of estrogen at 50% inhibition in the ELISA equals the reciprocal of the association constant, K, The specificity and affinity of four monoclonal antibodies for use in the assays of the present invention are given in Table 1 All antibodies demonstrated similar apparent reactivities with 160HE1 and 160HEl-3-glucuronιde (100 ± 15%), and of the twelve metabolites tested, significant cross-reactivity of about 3% was seen for only 5-androsten-3B,16c.-diol-17-one and 5α-androstan-3β,16β-dιol-17-one These 16α-ol-17-one androgens cross-react because their flat A/B- rings and equatorial 3-hydroxyl groups allows them to partially "fit" the antι-160HEl antibody binding site These metabolites are only found at measurable concentrations durmg the last trimester of pregnancy The affmities (K a ) of the monoclonal antibodies varied from 0.5 to 5 X 10" L/Mole The isotype of all antibodies to said 160HE1 -glucuromde fraction is IgG, with lambda light chain All cell lines which bound 20HE1 -alkaline phosphatase underwent at least two subclonings by limiting dilution to msure monoclonahty prior to characterization Specificities of antibodies to 20HE1 metabolites were determined by a competitive inhibition ELISA, but with decreasing concentrations of (10 to 0 ug/mL) of the estrogen, to be tested for cross-reactivity, as described above for monoclonal antibodies to 160HE1 Monoclonal antibodies to 20HE1 were tested for specificity against 20HE1 conjugates and against structurally related estrogens, particularly against 2-methoxylated steroids Monoclonal antibodies for use in the present invention were selected to react nearly equivalently with 20HE1 and 3-substιtuted 20HE1, that is to react with said 20H El -glucuromde fraction Not all monoclonal antibodies to 20HE1 generated as described above demonstrated specific reactivity with the said 20HE1 -glucuromde fraction The relative affmities of monoclonal antibodies to 20HE1 metabolites were determmed by domg the competitive inhibition ELISA with decreasmg amounts of 20HE1 (1000 to 0 pg/mL) the presence of a fixed amount of 20HE1 -alkaline phosphatase and monoclonal antibody in die wells of a microtiter plate (see Competitive Direct Enzyme-linked Immunoassay, above) The specificity and affinity of one monoclonal antibody to 20HE1 -glucuronide fraction for use accordmg to the present mvention is given in Table 2 The antibody demonstrates similar apparent reactivities with 20HE1 and 20HEl-3-glucuromde (80%), and of the 10 metabolites tested, sigmficant cross-reactivity was seen for all other 2-hydroxylated estrogens, 2-hydroxyestradιol and 2-hydroxyestπol The affinity (K,) of the monoclonal antibody is about 1 x 10" L/Mole The isotype of all antibodies to said 20HE1- glucuronide fraction is IgG, with kappa light chains The specificity and affinity of one monoclonal antibody to 2MeoEl -glucuronide fraction, 9D3, for use according to the present invention is given in Table 3 The antibody demonstrates similar apparent reactivities with 2MeoEl and 2MeoEl-3-glucuromde (120%), and of the 10 metabolites tested, sigmficant cross-reactivity was seen for all other 2-methoxylated 2-hydroxy estrogens, 2-methoxy 2- hydroxyestradiol and 2-methoxy 2-hydroxyestπol. The affinity (K a ) of the monoclonal antibody is about 2 x 10" L/Mole The isotype of all antibodies to said 2MeoEl -glucuronide fraction is IgG, 2b (mixed type) with lambda light chains TABLE 1 Specificity and Affinity of Monoclonal Antibodies to 16α -Hydrox estrone % CROSS-REACTIVITY TABLE 2 Specificity and Affinity of Monoclonal Antibody to 2-Hydroxyestrone % CROSS-REACTIVITY Monoclonal Antibody Designation Steroid Metabolite 4C11 l,3,5[10]-Estratrien-3-ol-17-one 100.0 (20HE1) l ,3,5[10]-Estratrien-3-ol-17-one-3-glucuronide 80.0 (20HEl-3-glucuronide) l ,3,5[10]-Estratrien-3, 17β-diol-2 100.0 (20HE2) l ,3,5[10]-Estratrien-2,3, 16, 17β-tetrol 70.0 (20HE3) l,3,5[10]-Estratrien-3,4-diol-17-one 2.1 l ,3,5[10]-Estratrien-3,16α, 17β-triol 0.2 1 ,3 ,5 [ 10] -Estratrien-3 , 17β-diol- 16-one 0.0 l,3,5[10]-Estratrien-3-ol-17-one 0.2 l ,3,5[10]-Estratrien-3, 17β-diol 0.0 l ,3,5f l0]-Estratien-2,3-diol-17-one 2-methyl ether 0.0 ISOTYPE ( IgGI , kappa light chain) IgGI AFFINITY (K., L/mole X 10") 1.0 TABLE 3 Specificity and Affinity of Monoclonal Antibody to 2-Methoxyestrone % CROSS-REACTIVITY Monoclonal Antibody Designation Steroid Metabolite 9D3 l ,3,5[10]-Estratrien-3-ol-17-one-2-methoxy 100.0 (2MeoEl) 1 ,3,5[ 10]-Estratrien-3-ol-17-one-2-methoxy 120.0 -3-glucuronide (2MeoE 1 -3-glucuronide) l ,3,5[10]-Estratrien-3, 17β-diol-2-methoxy 100.0 (2MeoE2) 1 , 3 , 5 [ 10] -Estratrien-3 , 16, 17β-triol-2-methoxy 70.0 (2MeoE3) l,3,5[10]-Estratrien-17-one-2.3-dimethoxy <0.1 l ,3,5[10]-Estratrien-3, 16o, 17o-triol 0.0 l ,3,5[10]-Estratrien-3.17β-diol-16-one 0.0 l ,3,5[10]-Estratrien-3.16α, 17β-triol 0.0 l,3,5[10]-Estratrien-3, 17β-diol 0.0 l,3,5[10]-Estratrien-3-ol-17-one 0.0 ISOTYPE ( IgG 1,2b; lambda light chain) 1 ,2b AFFINITY (K-, L/mole X 10") 2.0 Direct ELISA for said 160HEl-glucuronιde Fraction in Serum Polystyrene microtiter plates (96 well, C96 Maxisorb plate, NUNC, Napierville, IL USA) were coated with 200 ng/well affinity purified rabbit anti-mouse IgG, Fc-fragment specific antibody (Jackson Immunoresearch, West Grove PA USA) in PBS and incubated overmght at room temperature The plates were washed with PBS, blocked with 0 5% casern (w/v) in PBS, and stored wet until use Assay Standards were prepared by serial dilution of 160HEl-3-glucuronιde in steroid-free (charcoal-extracted) human serum at concentrations ranging from 7 8 to 1000 pg/mL Preparation of charcoal -extracted serum is a well established procedure m the diagnostic arts For assay, twenty-five uL of serum, Standards, and Positive and Negative Controls were aliquoted in duplicate mto an 8 x 12 aπay of racked 1 2 mL microtubes (CalCon Incoφorated, Claremont, CA USA) Microtubes are arranged in a pattern congruous with that of the ELISA plate assay wells such that liquid may be transferred directly from tubes to the assay well with an eight-channel pipettor Sample aliquots were diluted 1 7 (v/v) by addition of 150 uL of 0 05M 2-[Moφholιno]ethanesulfomc acid (MES) buffered saline (MESBS), pH 6 5, 2 mM EGTA, 5 mM ascorbic acid, 50 ng/mL dehydrotestosterone (DHT) contammg 3 ng/mL of purified monoclonal antibody (Sample Diluent) Diluted sera samples were covered and incubated at 38 deg C in a water bath for one hour After cooling for 15 minutes, 75 uL of standards, controls, and unknowns were transferred to wells of a washed rabbit anti-mouse IgG Fc antibody-coated microtiter ELISA plate with an eight-channel pipettor To these wells was then added and additional 75 uL of a 1 2000 dilution (v/v) of 160HE1 -labeled AP (3000 U/mL) in Tπs-buffered salme, pH 6 9, (TBS) contaimng 0 1 % gelatin, pH 6 5 (Conjugate Diluent), and plates were covered and incubated overnight at 4 deg C Plates were washed six times with TBS containing 0 05% Tween-20, and 150 uL of AP Enzyme Substrate conta mg 2 mM paranitrophenol phosphate (pNPP) in IM diethanolamine was added to quantify 160HEl-labeled AP bound to the plate Absorbance at 450 nm was read with an automated ELISA plate reader after 30 minutes The concentration of said 160HE1- glucuronide fraction in unknowns was determmed by reference and extrapolation from the standard curve using a four-parameter logistic curve fittmg program (Kineti-Calc, Biotek Instruments, Wynooski, VT USA) Direct ELISA for Total 16QHE1 -Glucuronides in Serum The assay for total 160HE1 -glucuronides in serum is done exactly as described above, except that all 160HE1 -glucuronides, both 3- and 16-glucuronιdes are deconjugated, that is, the glucuronides removed from estrogens m serum, prior to performing the ELISA Standards for this assay are prepared by serial dilution of 160HE1 in charcoal-extracted serum at 7.8 to 1000 pg/mL. Cleavage of steroidal glucuronides is achieved by incubation wim the enzyme β-glucurorudase, preferably that isolated from the bacteria, E. Coli. In practice, E. Coli β-glucuromdase (Sigma Chemical Company, St. Louis MO USA), 1000 U/mL, is added to me MESBS serum dilution buffer, and the assay performed exactly as described above for Direct ELISA for 160HEl-3-glucuromde Fraction. By this modification of the prefeπed assay of this invention, concentrations detected and /or quantified by direct ELISA with antibodies of this mvention will be equal to or greater than those found by direct ELISA for said 160HE1 -glucuronide fraction (no deconjugation). Each of the two direct ELISA formats described above, when utilized with monoclonal antibodies described above, will find greatest use m various situations. For example, the direct ELISA for said 160HE1 -glucuronide fraction is preferable when used for the diagnosis/ prognosis of neoplastic diseases Different pathological states, as, for example, neoplastic versus autoimmune disease, may be associated with distinctive patterns of 160HE1 conjugation. Different enzyme pretreatment of 160HE1 metabolites in body fluids, therefore, may be required to optimally distmguish and detect specific pathological conditions. APAAP Immunocytochemical Assav for lόOHEl-glucuronide Fraction m Tissue Sections Sections of 5 to 10 micron thickness cut from paraformaldehyde-fixed, paraffin-embedded tissues with a microtome are mounted on dry glass slides previously treated with 5% swine serum in PBS Slides are heated at 60 degrees C. for 30 mmutes and dewaxed immersion in xylene for 5 mm. Tissues sections on slides are rehydrated by repetitive immersion in a graded series of ethanol/water solutions 100 % ethanol (3 mm.); 95% ethanol (3 mm.); 70% ethanol (3 mm); and, finally, PBS (2 X 3 min.) Rehydrated tissues are immediately overlaid and incubated with 100 uL of monoclonal antibody at 5 ug/mL in TBS (Anti-lόOHEl Antibody Solution) for 30 min at room temperature. Slides are then washed by immersion m TBS (6 x 3 mm) to remove antibody not bound to said 160HE1 -glucuronide fraction in tissue sections One hundred uL of a solution containing polyclonal rabbit anti-mouse IgG Antibody Bridging Solution (DAKO Coφoration, Caφenteπa CA USA) in PBS is overlaid onto each tissue section, and incubated for 1 hr at room temperamre. Slides with tissues are washed as in the previous step and tissues overlaid with a 100 uL aliquot of alkaline phosphatase :antι-alkalιne phosphatase (APAAP Complex) (DAKO) in TBS for 30 mm. The optimal dilution of anti-mouse IgG antisera (Antibody Bridging Solution) and APAAP Complex should be determined by titration, but should be about 1.25 in TBS, pH 7 4 After washing, tissues are incubated with 100 uL of napthol AS-MX/Fast Red Enzyme Substrate for 10 mm. The enzyme substrate is prepared as follows. Dissolve 2 mg napthol AS-MX phosphate (Sigma Chemical Company, St Louis MO USA) in 0 2 mL of N,N-dιmethyl formamide in a glass mbe, and add 10 mL of 0 1 M TBS, pH 8.2 (Enzyme Substrate Solution) Immediately before use, dissolve Fast Red TR salt (Sigma) at 12 mg/mL m the napthol AS-MX solution and apply to the washed slides Endogenous alkaline phosphatase activity m the mammalian tissues may be inhibited by adding 1 mM levamisole (Sigma) to the later solution After an mtense red color develops, substrate is washed from e slide with water, and after blottmg excess liquid, the tissues are preserved on the slides by mountmg with glycerol vmyl alcohol solution (GVA Mount, Zymed, San Francisco CA USA) and covers pped for permanent storage Direct ELISA for said 2QHE1 -glucuromde Fraction ιn_Ssmm The assay is done in a manner very similar to that for 160HEl-glucuronιde fraction (above) Polystyrene microtiter plates were coated with affinity purified rabbit anti-mouse IgG, Fc-fragment specific antibody in PBS and mcubated overmght at room temperamre The plates were washed with PBS, blocked with 0 5 % casern (w/v) in PBS, and stored wet until use Assay Standards were prepared by serial dilution of 20HEl-3-glucuronιde m steroid-free (charcoal-extracted) human serum at concentrations ranging from 7 8 to 1000 pg/mL For assay, twenty-five uL of serum, Standards, and Positive and Negative Controls were aliquoted in duplicate into an 8 x 12 aπay of racked 1 2 mL microtubes Sample aliquots were diluted 1 7 (v/v) by addition of 150 uL of 0 05M 2-[Moφholιno]ethanesulfonιc acid (MES) buffered saline (MESBS), pH 6 5, with EGTA and ascorbate (as above) contaimng 3 ng/mL of purified monoclonal antibody (Sample Diluent) Diluted sera samples were covered and incubated at 38 deg C in a water bath for one hour After cooling for 15 minutes, 75 uL of standards, controls, and unknowns were transferred to wells of a washed rabbit anti-mouse IgG Fc antibody-coated microtiter ELISA plate To these wells was then added and additional 75 uL of a 1 2000 dilution (v/v) of 20HE1 -labeled AP (3000 U/mL) in TBS containing 0 1 % gelatin, pH 6 9 (Conjugate Diluent), and plates were covered and incubated overnight at 4 deg C Plates were washed six times with TBS contaimng 0 05% Tween-20, and 150 uL of AP Enzyme Substrate pNPP was added to quantify 20HE1 -labeled AP bound to the plate Absorbance at 450 nm was read after 30 minutes with an automated ELISA plate reader The concentration of said 20HE1- glucuronide fraction in unknowns was determmed by reference and extrapolation from the standard curve Direct ELISA for Total 2QHE1. 2QHE2. and 2QHE3-Glucuronιdes in Serum The assay for total 2-hydroxylated estrogen glucuronides in serum is done exactly as described for 20HE1 -glucuronides above, except that all 2-hydroxylated-glucuronιdes, including 20HE2- and 20HE3- glucuromdes are deconjugated, that is, the glucuronides removed from estrogens in serum, pπor to performing the ELISA This is possible because Mab 4C 11 recognizes all unconjugated 2-hydroxylated estrogens, not just the 20HE1. Standards for this assay are prepared by serial dilution of 20HE1 in charcoal-extracted serum at 7 8 to 1000 pg/mL Cleavage of steroidal glucuronides in serum is achieved by mcubation with the enzyme β-glucuronidase, preferably that isolated from me bacteria, E Colt In practice, E Colt β-glucuromdase, 1000 U/mL, is added to the MESBS serum dilution buffer, and the assay performed exactly as described above for Direct ELISA for 20HEl-3-glucuronιde Fraction B> this modification of the preferred assay of this invention, concentrations detected and /or quantified by direct ELISA with antibodies of this invention will be generally equal to or greater than those found by direct ELISA for said 20HE1 -glucuromde fraction (no deconjugation) Each of the two direct ELISA formats described above, when utilized with monoclonal antibodies described above, will find greatest use m various simations For example, the direct ELISA for said 20HE1 -glucuromde fraction is preferable when used for the diagnosis/ prognosis of neoplastic diseases Different pathological states, as, for example, neoplastic versus autoimmune disease, may be associated with distinctive patterns of 160HE1 conjugation Different enzyme pretreatment of 160HE1 metabolites in body fluids, therefore, may be required to optimally distinguish the glucuromde fraction and detect specific pathological conditions APAAP Immunocytochemical Assay for 20HE1 -glucuronide Fraction in Tissue Sections This method follows that for immunocytochemical detection for 160HE1 -glucuromde, above Sections of 5 to 10 micron thickness cut from paraformaldehyde-fixed, paraffin-embedded tissues with a microtome are mounted on dry glass slides previously treated with 5% swine serum in PBS Slides are heated at 60 degrees C for 30 mmutes and dewaxed immersion in xylene for 5 min Tissues sections on slides are rehydrated by repetitive immersion in a graded series of ethanol/water solutions 100 % ethanol (3 min ), 95% ethanol (3 mm ), 70% ethanol (3 mm); and, finally, PBS (2 X 3 min ) Rehydrated tissues are immediately overlaid and incubated wim 100 uL of monoclonal antibody at 20 ug/mL m TBS (Anti- 20HE1 Antibody Solution) for 30 mm at room temperamre Slides are then washed by immersion in TBS (6 3 min) to remove antibody not bound to said 20HE1 -glucuronide fraction in tissue sections One hundred uL of a solution contammg polyclonal rabbit anti-mouse IgG Antibody Bridging Solution in PBS is overlaid onto each tissue section, and incubated for 1 hr at room temperature Slides with tissues are washed as in the previous step and tissues overlaid with a 100 uL aliquot of alkaline phosphatase anti- alkaline phosphatase (APAAP Complex) in TBS for 30 min After washing, tissues are incubated with 100 uL of napthol AS-MX/Fast Red Enzyme Substrate for 10 min The enzyme substrate is prepared as follows Dissolve 2 mg napthol AS-MX phosphate (Sigma Chemical Company, St Louis MO USA) in 0.2 mL of N,N-dimethyl formamide in a glass tube, and add 10 mL of 0.1 M TBS, pH 8.2 (Enzyme Substrate Solution). Immediately before use, dissolve Fast Red TR salt (Sigma) at 12 mg/mL in the napthol AS-MX solution and apply to the washed slides. Endogenous alkaline phosphatase activity in the mammalian tissues may be inhibited by adding 1 mM levamisole (Sigma) to the later solution. After an intense red color develops, substrate is washed from the slide with water, and after blotting excess liquid, the tissues are preserved on the slides by mounting with glycerol vinyl alcohol solution and coverslipped for permanent storage. Direct ELISAs for 2MeoEl -Glucuronide Fraction in Serum The assay for 2MeoEl -glucuronide fraction in serum is done exactly as described above for 160HE1- glucuronide fraction, except that antibody to 2MeoEl (9D3), 3 ng/mL, is used with 2MeoEl -labeled- AP (1 :2000). Standards for this assay are prepared by serial dilution of 2MeoEl-3-glucuronide in charcoal - extracted serum at 7.8 to 1000 pg/mL. Direct ELISA for Total 2-Methoxvlated 2QHE1 -. 2QHE2-. and 2QHE3-Glucuronide Fractions in Serum The assay for total 2-methoxylated 2-hydroxyestrogen glucuronides in serum is done exactly as described for 2MeoEl -glucuronides above, except that all 2-methoxylated-glucuronides, including 2MeoEl-, 2MeoE2- and 2MeoE3-glucuronides are deconjugated, that is, the glucuronides removed from estrogens in serum, prior to performing the ELISA. This is possible because Mab 9D3 recognizes all unconjugated 2-methoxylated estrogens, not just the 2MeoEl . Standards for this assay are prepared by serial dilution of 2MeoEl in charcoal-extracted serum at 7.8 to 1000 pg/mL. Cleavage of steroidal glucuronides in serum is achieved by incubation with the enzyme β-glucuronidase, preferably that isolated from the bacteria, E. Coli. In practice, E. Coli β-glucuronidase, 1000 U/mL, is added to the MESBS serum dilution buffer, and the assay performed exactly as described above for direct ELISA for 2MeoEl-3- glucuronide Fraction. By this modification of the preferred assay of this invention, concentrations detected and /or quantified by direct ELISA with antibodies of this invention will be equal to or greater than those found by direct ELISA for said 2MeoEl -glucuronide fraction (no deconjugation). This assay format, in fact, measures the sum of 2MeoEl , 2MeoE2 (2-methoxyestradiol), and 2MeoE3 (2- Methoxyestriol) glucuronide fractions, and is, therefore, also an assay for this fraction in serum. Each of the two direct ELISA formats described above, when utilized with monoclonal antibodies described above, will find greatest use in various situations, some described in the follwing examples. EXAMPLE 1 Normal and Breast Cancer Sera in Direct ELISA for 16QHE1 -Glucuronide Fraction Seventeen sera from healthy women not taking estrogens or other drugs (from Jewish Hospital, St. Louis MO USA), and 28 sera from women with pathologically confirmed and staged breast cancer tumors at the time when serum was collected (from Case Western Reserve, Cleveland, Ohio, USA, and Ohio State University, Columbus, Ohio, USA) were assayed by the direct competitive assay for the 160HE1- glucuronide fraction, herein after called "serum 160HE1 " as described above, and the results shown graphically in FIGURE 5. Serum from these patients was collected on the day of surgery to remove the tumors by mastectomy. Most of the surgeries were performed subsequent to earlier biopsies or lumpectomies that removed portions of the breast tumors. Only those women who were found to have residual malignant tissues are included in this study. The average of serum 160HE1 for 28 women with breast cancer tumors was about 200 pg/mL (TABLE 4). The presence or absence of mmor cell metastases to the lymphatic nodes system was known in these patients, that is, whether they were node positive or node negative, respectively. The 11 patients with positive nodes and 17 node negative patients both had about 200 pg/mL serum 160HE1. The levels of serum 160HE1 in 11 healthy postmenopausal women was about 60 pg.mL, with none of the women having serum 160HE1 -glucuronide fraction above 140 pg/mL. Nine of 11 (81 %) node positive women had serum 160HE1 -glucuronide fraction greater than 140 pg/mL, and the same fraction of node negative women had serum values in excess of 140 pg/mL. This data indicates that serum 160HE1 -glucuronide fraction is a marker for the potential presence of a breast cancer mmor. Odds Ratio analysis indicates that a woman with serum 160HE1 > 140 pg/mL would have at least an eight-fold higher risk of developing breast cancer. It also follows that the higher the level of serum 160HE1 in a woman, the greater is the likelihood of the disease and/or occult tumor mass. These results further illustrate the utility of the level of serum 160HE1 (the glucuronide fraction) as a tumor marker, and 160HE1 -glucuronide fraction as a rumor-associated antigen. TABLE 4.: Patients' ages and serum lόαOHEl concentration CONTROLS CONTROLS BENIGN BREAST CANCER (Premeno.) (Premeno.) TUMOR Node - Node+ (Ν=12) (N = 16) (N= 12) (N= l l) (N= 16) DETAILS AGE (Yr) 32 (11.6)* 65.2(7.8) 62.5(6.9) 69.8(8.4) 68.8(7.9) I60OHEI 184(50.2) 60.8(39.1) 83.8(81.1) 192.0(106.0)**202.1(112 9)*** * Mean (SD). ** p< 0.0003 and p<0.01 for Node - versus Controls and Bemgn Tumor, respectively by one sided Mann- Whitney U-test. *** p< 0.0001 and p< 0.003 for Node + versus Control and Benign Tumor, respectively. EXAMPLE 2 Normal and Breast Cancer Sera in Direct ELISA for Total Serum 16QHE1 -Glucuronide The same sera as used in Example 1, above, were assayed for total serum 160HE1 -glucuronide by the ELISA described above. This assay differed from that used in Example 1 in that prior deconjugation with β-glucuronidase allows detection and/or quantification of 160HEl-3, 16-glucuronιdes in addition to the said 160HE1 -glucuronide fraction. The average total serum 160HE1 glucuronide for 11 healthy postmenopausal women was 142 ± 35 pg/mL, as compared to 201 ± 93 pg/mL for the node positive breast cancer patients, and 133 ± 33 pg/mL for the node negative patients (see FIGURE 6). There is less discrimination between normals and node positive breast cancer patients groups for total serum 160HE1 -glucuronide than for serum 160HE1- glucuronide fraction. This appears to be due to a greater amount of serum 160HEl-3,16-glucuronιdes. as shown graphically in FIGURE 2, as compared to the amount of 160HE1 -glucuro de fraction m healthy women, as shown graphically in FIGURE 2. The direct ELISA of 160HE1 -glucuronide fraction is, therefore, preferred for detection of elevations in serum 160HE1 metabolites in breast cancer. The ELISA for total 160HE1 -glucuronides, however, may prove useful in certain circumstances, as in other body fluids such as breast aspirates, or other types of malignancies, or diseases. EXAMPLE 3 Fixed Normal and Breast Cancer Tissue in APAAP Direct Immunocytochemical Assav for 160HE1- GLucuronide Fraction Formalin-fixed paraffin-embedded breast tissue blocks from 12 healthy women undergoing breast reduction surgery, and blocks of breast tumor tissue and matched Near Adjacent Tissue (NAT) from 8 women with breast cancer were obtained from Ohio State University, Columbus, OH USA. The NAT is collected from tissues that immediately surround the solid breast mmors, and is used to define the margins and extent of mmor. Tissue blocks were sectioned, dewaxed and stained for 160HE1- glucuronide fraction as described above in APAAP Immunocytochemical Assay for said 160HE1- glucuronide Fraction in Tissue Sections. Both mmor and matched NAT were stained for each mmor. Each tissue section was stained with four reagents: 1) monoclonal antibody to 160H El -glucuronide fraction; 2) monoclonal antibody to 160HE1 -glucuronide fraction with excess 160HE1 added; 3) monoclonal antibody to 160HE1 -glucuronide fraction with excess estradiol added; and 4) nonimmune polyclonal mouse IgG at same concentration as specific monoclonal antibody. These last three stains acted as controls for specific and nonspecific staining. Thus, a patte of specific staining would see: 1) positive; 2) negative; 3) positive; and 4) negative. The intensity of staining is ranked subjectively as negative (-), weakly positive (+/-), positive (+), and strongly positive ( + +). Examples of breast tissues stained for 160HE1 are illustrated in FIGURES 7A and 7B wherein a breast cancer near adjacent tissue (NAT) and tissue from a normal breast are stained for 160HE1 -glucuronide fraction according to the APAAP direct immunocytochemical assay method of this invention. The breast tumor (NAT) tissue (Patient 7893) demonstrates bright red staining surrounding the ductal elements, whereas the normal tissue of similar structure (Patient Co37) is totally unstained. Photographs were taken at 845X magnification on Kodak daylight film using a Wratten 80A filter and tungsten light source. Tissues were counterstained with hematoxylin/eosin. As illustrated in Table 5, all (100%) of the breast cancer tissues stain positively for lόOHE-glucuronide fraction, and the near adjacent tissues (NAT) all stain strongly ( + +). The pattem of staining indicates that the greatest amount of 160HE1 -glucuronide fraction is found not in mmor, but in the NAT in which 40-100% of the sections stain, especially at the periphery of the malignant ductal and lobular structures. Of the 12 normal breast tissues, only 3 of 12 (25%) slow weak ( + /-) staining for 160HE1 -glucuronide fraction, and in those cases staining is limited to hypeφlastic, ectasic, or fibrocystic foci in breasts. The difference in staining between normal and cancerous tissues is highly significant (p < 0.009). Staining in normal breast tissues is not associated with or proximal to ductal or lobular elements as is seen in breast cancer. As illustrated in Table 5, the presence of 160HE1 -glucuronide in breast carcinoma is not dependent upon the estrogen receptor stams of mmor cells, as 4 of 8 (50%) tumors expressed estrogen receptors (ER), but all (100%) of the tumors stain strongly for 160HE1 -glucuronide fraction. These findings further support consideration of said 160HE1 -glucuronide fraction as a mmor marker and mmor associated antigen. Immunohistochemical staining for 160H El -glucuronide fraction in breast cancer mmors, near adjacent tissues, and lymph nodes may be useful in determining the prognosis of a specific tumor, especially when used in conjunction with serum assays for serum 160HE1 -glucuronide fraction; high levels of 160HEl-glucuronide fraction in tissues and serum could thus be considered as predictive for metastatic potential of a mmor. TABLE 5 lόOHEl-Glucuronide Fraction in Malignant and Normal Breast: Results in Formalin-Fixed Paraffin-embedded sections Breast Cancer Controls* P-value** Fraction Positive (%)*** for 16aOHEl : 100 % (8/8, + + ) 25% (3/12 , +/-) 0.009 ER Status: (4/8 ER + ) (12/12 ER + ) * Normal breast tissues were obtained from breast reduction surgery. * * Kolmogorov-Smirnov Two-Sample Test * ** Tissues were scored positive if more than 10% of cells stained. EXAMPLE 4 Normal and Breast Cancer Sera in Direct ELISA for 2QHE1 -Glucuronide Fraction Ten sera from healthy women not taking estrogens or other drugs (from Jewish Hospital, St. Louis MO USA), and 16 sera from women with a history of breast cancer mmors udergoing mastectomy (from Case Western Reserve, Cleveland, Ohio, USA, and Ohio State University, Columbus, Ohio, USA) were collected prospectively and assayed by the direct competitive assay for the 20HE1 -glucuromde fraction, herem after called "semm 20HE1 " as described above The results are shown graphically in FIGURE 8 Most of the surgeries were performed subsequent to earlier biopsies or lumpectomies that removed portions of the breast mmors The average of semm 20HE1 for 8 postmenopausal women with localized, non-metastatic breast cancer mmors was about 140 pg/mL semm 20HE1 -glucuromde fraction The presence or absence of mmor cell metastases to the lymphatic nodes system was known in these patients, that is, whether they were node positive or node negative, respectively The 8 age-mathched women with positive nodes had about 53 pg/mL semm 20HE1 The levels of semm 20HE1 in 8 postmenopausal women with node negative disease were about 103 pg/mL, with none of the women having semm 20HE1 -glucuronide fraction above 170 pg/mL The average semm 20HE1 for the postmenopausal controls was highest of all groups, about 137 pg/mL semm The semm 20HE1 levels in node positive breast cancers were lower than the controls (p <0 001) and node negative breast cancer group (p <0 05), respectively (FIGURE 8) This data indicates that semm 20HE1 -glucuromde fraction is a marker for the potential metastatic spread of a breast cancer mmor Odds Ratio analysis indicates that a breast cancer patient with semm 20HE1 < 80 pg/mL would have at least a five-fold higher risk of developmg metastatic breast cancer The estrogen receptor stams of the mmor must be considered, however It also follows that the lower the level of semm 20HE1 in a woman with breast cancer, the greater is the likelihood of metastatic spread of disease and/or occult mmor mass Thee may be other situations, however, as in very earl\ stage breast cancer, in which an elevated level of semm 20HE1 may indicate the presence of an occult mmor These results further illustrate the utility of the level of semm 20HE1 (the glucuronide fraction) as a marker for progression in estrogen sensitive malignancies EXAMPLE 5 Normal and Breast Cancer Tissue in APAAP Direct Immunocytochemical Assav for 2QHE1 -Glucuronide Fraction Formalin-fixed paraffin-embedded breast tissue blocks from 12 healthy women undergoing breast reduction surgery, and blocks of breast tumor tissue and matched Near Adjacent Tissue (NAT) from 8 women with breast cancer were obtained from Ohio State University, Columbus, OH USA Tissue blocks were sectioned, dewaxed and stained for 20HE1 -glucuronide fraction as described above in APAAP Immunocytochemical Assav for said 2QHE1 -glucuronide Fraction in Tissue Sections Both mmor and matched NAT were stained for each mmor Each tissue section was stained with four reagents 1) monoclonal antibody to 20HE1 -glucuromde fraction, 2) monoclonal antibody to 20HE1 glucuromde fraction with excess 20HE1 added, 3) monoclonal antibody to 20HE1 -glucuronide fraction with excess estradiol added, and 4) nonimmune polyclonal mouse IgG at same concentration as specific monoclonal antibody These last three stams acted as controls for specific and nonspecific staining Thus, a pattem of specific staimng would see 1) positive, 2) negative, 3) positive, and 4) negative The intensity of staimng is ranked subjectively as negative (-), weakly positive (+/-), positive (+), and strongly positive (+ +) Examples of breast tissues stamed for 20HE1 are illustrated in FIGURES 9A and 9B wherein a breast cancer mmor tissue and tissue from a normal breast are stained for 20HE1 -glucuromde fraction accordmg to the APAAP direct immunocytochemical assay method of this mvention The breast tumor tissue (Patient 7450) demonstrates no staimng of mmor cells, but nuclear staimng of cells within an isolated duct of normal moφhology (FIGURE 9A) The normal tissue, unlike the tumor, shows numerous normal ducts in which the nuclei stam strongly for 20HE1 -glucuronide fraction (Patient Co78) Photographs were taken at 845X magmfication on Kodak daylight film usmg a Wratten 80A filter and tungsten light source Tissues were counterstained with hematoxyhn/eosin All (100%) of the normal breast tissues stamed positively for 20HE1 -glucuromde fraction, demonstrating localization of 20HE1 to the nuclei of ductal epithelial cells By contrast, 8/8 (0%) of the breast tumor tissues stamed for 20HE1 The NAT to all mmors stained positively ( + ) for 20HE1 Of the 12 normal breast tissues, 12 of 12 (100%) showed (+) staimng for 20HE1 -glucuronide fraction, and in those cases staining was limited to nuclei of ductal cells, and cytoplasm of normal stromal tissues (TABLE 6) TABLE 6. 20HEl-Glucuronide Fraction in Malignant and Normal Breast: Results in Formalin-Fixed Paraffin-embedded sections Breast Cancer Controls* P-value** Fraction Positive (%)*** for 20HE1 0 % (8/8, -) 100 % (12/12 ,+ to ++) 0 000 ER Status (4/8 ER+) (12/12 ER+) * Normal breast tissues were obtained from breast reduction surgery ** Kolmogorov-Smirnov Two-Sample Test *** Tumor tissues scored positive if more than 10% of nuclei of cells stained These findings further support consideration of said 20HE1 -glucuronide fraction as a mmor marker and mmor associated antigen Immunohistochemical staimng for 20HE1 -glucuro de fraction in breast cancer mmors, near adjacent tissues, and lymph nodes may be useful in determining the prognosis of a specific mmor, especially when used m conjunction with semm assays for semm 20HE1 -glucuromde fraction, high levels of 20H El -glucuromde fraction in tissues and semm could thus be considered as predictive for metastatic potential of a mmor EXAMPLE 6 Normal and Breast Cancer Sera m Direct ELISA for 2MeoEl -Glucuronide Fraction Twenty sera from healthy women not talcing estrogens or other dmgs (from Jewish Hospital, St Louis MO USA), and 12 sera from women with pathologically confirmed and staged breast cancer mmors at the time when semm was collected (from Case Western Reserve, Cleveland, Ohio, USA, and Ohio State University, Columbus, Ohio, USA) were assayed by the direct competitive assay for 2MeoEl- glucuromde fraction, herem after called "semm 2MeoEl ", and the data graphical shown in FIGURE 10 Semm from these patients was collected on the day of surgery to remove the tumors by mastectomy Most of the surgeries were performed subsequent to earlier biopsies or lumpectomies that removed portions of the breast mmors Only those women who were found to have residual malignant tissues are included in this study The average of semm 2MeoEl for 20 healthy women was 24 + 13 pg/mL (± Standard Deviation) The presence or absence of mmor cell metastases to the lymphatic nodes system was known in these patients that is, whether they were node positive or node negative, respectively The 7 patients with positive nodes had an average of 75 ± 15 pg/mL semm 2MeoEl , whereas 4 of 5 (80%), of the node negative patients had very significantly elevated semm 2MeoEl (250 ± 181 pg/mL) The difference between the node -I- and node - groups was highly significant (p < 0 005, t-test) These data suggest that semm 2MeoEl -glucuronide fraction is a marker for metastatic potential of a breast cancer tumor, but an opposite sense to that of semm 160HEl-glucuronιde fraction Odds Ratio analysis indicates that breast cancer patients with semm 2MeoEl < (less than) 120 pg/mL would have at least a four-fold higher risk of having metastatic disease EXAMPLE 7 longitudinal Monitoring of Chemotherapy of Breast Cancer with Direct ELISAS for 2QHE1-. 2MeoEl-. and 16QHEl-glucronιde fractions. Serially collected semm samples (Bioclinical Partners, Waltham, MA USA) from two women undergomg chemotherapy for metastatic breast cancer were assayed for 20HE1-, 2MeoEl-, and 160HE1 -glucuromde fractions by ELISAs of the present invention as described above Donor 13246 was a 76 year old woman with stage III breast cancer She initially received a chemotherapy course with CMF (Cytoxan Methotrexate/5-Flourouracιl combmation) treatment, followed by a series of treatments wim adπamycin (FIGURE 11) Clinically objective parameters indicated disease stability durmg CMF therapy, but relapse and progression soon after initiation of adπamycin treatments Semm 160HE1 glucuronide fractions were elevated above normal, and fell slightly during CMF therapy By contrast, semm 20HE1- and 2MeoEl -glucuronide fractions mcreased under CMF admmistration, but like 160HE1 , decreased abmptly after the initial treatment with adπamycin (FIGURE 11 After this declme m all semm glucuromde fractions, however, the 160HE1 semm levels rebounded shaφly upward, whereas 20HE1 and 2MeoEl concentrations remained depressed relative to levels before adπamycin treatments Donor 1709 was a 77 year old woman with advanced stage IV breast cancer During me l tal phases of serial momtormg, the disease, while advanced, was considered stable (FIGURE 12) At a later time, however, a breif course of adπamycin was initiated This treatment was poorly tolerated and/or ineffective, and a follow-up course of haotestm, an androgenic steroid, was given Growth of the tumor in this woman was discovered to be progressing soon after initiation of adπamycin treatments(FIGURE 12) Semm 160HE1 glucuronide fraction was abnormally elevated initially in this woman, but declined somewhat prior to the beginning of first the chemotherapy treatment After the initial adπamycin treatment, 160HE1 increased shaφly to a maximum, and then declined By contrast, 20HE1- and 2MeoEl -glucuronide fractions declined steadily after adπamycin treatments It was at this time that clinical parametrs and tests indicated that me disease was in the early stages of progression (FIGURE 12) The levels of 160HE1 were unaffected by haotestm therapy, but semm 20HE1- and 2MeoEl- glucuronide fractions increased shaφly The above results suggest that a rising semm 160HEl-glucuronιde fraction where accompanied b\ relatively low levels of 20HE1- and/or 2MeoEl -glucuronide fractions is predictive for progression of tumor growth in estrogen-sensitive cancers There may be other circumstances, however, in which the glucuronide fractions may change in a different, yet predictive manner upon exposure to chemotherapy or other agents Assays of the present invention as described herein will, therefore, find broad utility in monitoring and predictmg the clinical course of estrogen-sensitve cancers, including but not limited to cervical, ovarian, endometrial, uterme, and breast cancer EXAMPLE 8 ELISA Test Kit for 16QH El -Glucuro de Fraction in Semm All materials and reagents to perform the ELISA for semm 160HE1 -glucuromde are preferably packaged together in a single kit The kit includes an antibody-coated microtiter plate (anti-mouse IgG Fc-specific antibody), a microtube rack (96 X 1 2 mL tubes), two adhesive microtiter plate covers. Sample Diluent contammg monoclonal antibody to 160HE1 -glucuronide fraction (21 mL), Enzyme Conjugate Diluent (10 mL), 160H El -labeled-alkaline phosphatase (AP) (20 ul in 0 5 mL vial), AP Enzyme Substrate (paramtropheny -phosphate, pNPP) (21 ml), 160HEl-3-glucuromde Standards (25 - 800 pg/mL) in charcoal-extracted semm (6 x 300 ul/vial), Positive Controls (2 x 300 ul/vial), a Negative Control (300 ul/vial), and Instmctions for use of the Kit The kit will determine semm 160H El -glucuronide in thirty- two semm samples Compositions of kit components are as described in Direct ELISA for said 160HE1- glucuromde Fraction in Semm. above EXAMPLE 9 APAAP Immunocytochemical Test Kit for 16QHEl-glucuron.de Fraction in Tissues All materials and reagents for immunostaining for 160H El -glucuronide fraction in fresh and/or paraffin- embedded fixed tissues may be brought together in a single kit The kit includes 100 glass slide pretreated with swine semm, Antι-160HE1 Antibody Solution (6 mL in dropper vial). Antibody Bridging Solution (6 mL in dropper vial), APAAP Complex (10 mL in dropper vial), Enzyme Substrate Solution (21 mL), 5 napthol AS-MX Fast Red TR tablets, GVA Mount Solution (10 mL), TBS Wash and Dilution Buffer (5 X 30 mL, salts for reconstitution), and Instructions for use of the Kit Negative and Posime Control Slides consisting of sectioned paraffin-embedded tissues mounted on swine serum-treated slides are included Compositions of kit components are as described in APAAP Immunocytochemical Assa\ for 16QHEl-glucuron.de Fraction in Tissue Sections, above The kit will enable staining of at least 50 tissue sections Vaπous modifications of this invention in addition to those shown and described herein will become apparent to those in the art from the foregoing description Such modifications are intended to be within the scope of the appended claims The references herein cited are hereby incoφorated by reference

Claims: WHAT IS CLAIMED IS 1 A method of screemng for a pathology in mammals wherem an alteration m estrogen metabolism is mdicative of the pathology or a susceptibility thereto which comprises A detectmg the level of a particular estrone metabolite and/or its 3-glucuronιde fraction from a biological sample taken from the mammal under exammation; and B comparmg this level with an extrinsic numerical value derived ei er previously from the mammal under testmg, or from the testmg of other subjects of the same species, to detect any differences in the level of the particular estrone metabolite and its glucuromde 2 The method of Claim 1 wherem said metabolites of estrone are selected from the group consistmg of products of enzymatic hydroxylation of estrone products of enzymatic reduction of estrone, products of enzymatic oxidation of estrone, and products of enzymatic methylation of estrone 3 The method of Claim 1 wherein said metabolites are selected from the group consistmg of 2- hydroxyestrone, 4-hydroxyestrone, 15α-hydroxyestrone, 16o -hydroxyestrone, 2-memoxyestrone, estriol, 17β-estπol, epiestπol, 16-ketoestradιol, estradiol, 15α-hydroxyestradιol, 2-hydroxyestradoιl, 2- hydroxy estriol, 2-methoxyestradιol, 2-memoxyestπol, and 4-methoxyestradιol 4 The method of Claim 1 wherein the 3-glucuronιde fraction is subjected to deconjugation with β- glucuronidase prior to analysis 5 The method of Claim 1 wherem said metabolites comprise 16-hydroxyestrone and its 3 glucuronide 6 The method of Claim 1 wherem said metabolites comprise 2 -hydroxyestrone and its 3- glucuronide 7 The method of Claim 1 wherem said metabolites comprise 2-methoxyestrone and its 3- glucuronide 8 The method of Claim 1 wherem said level is measured in semm 9 The method of Claim 8 wherem said level is measured by immunochemical analysis 10 The method of Claim 9 wherein said immunochemical analysis is a competitive inhibition immunoassay 11 The method of Claim 10 wherem said immunochemical analysis is a competitive enzyme-linked immunoassay (ELISA) using monoclonal antibodies and 160HEl-enzyme conjugates which comprises (a) addmg to a microtiter plate coated with monoclonal antibody to 160HEl/160HEl-3-glucuronιde an appropriately treated sample of patient semm mixed with an enzyme covalently labeled with 160HE1, (b) incubating the mixmre from (a) for a period of incubation permitting competition between 160HE1- enzyme and semm 160HE1 -glucuromde fraction for binding to monoclonal antibody bound to the solid phase, (c) washing the plate; (d) addmg to the washed plate a color-generating enzyme substrate to determine the amount of 160HE1- enzyme bound, (e) determining the quantity of 160H El -glucuronide fraction m each semm sample from the absorbance of the sample relative to a set of 160HE1 -glucuronide standards and controls of known concentration; and (f) comparing the level of the 160HE1 -glucuronide fraction in the semm sample to an extrinsic numerical value derived either previously from the patient under testing, or from the testing of other subjects of the same species, to detect any differences in the level of the particular estrone metabolite and its glucuromde standards previously determmed to ascertain the presence of abnormal levels of 160H El -glucuromde fraction mdicative of a pathology 12 The method of Claim 11 wherem the assay is buffered so as to be kept acidic to protonate said glucuromde fraction, thereby minimizing charge interactions with proteins in tissues and body fluids 13 The method of Claim 11 wherem the assay is performed at temperatures at or below 15 degrees Centigrade 14 The method of Claim 11 wherein said pathology is breast cancer 15 The method of Claim 10 wherein said immunochemical analysis is a competitive enzyme-linked immunoassay (ELISA) using monoclonal antibodies and 20HE1 -enzyme conjugates which comprises (a) adding to a microtiter plate coated with monoclonal antibody to 20HEl/20HEl-3-glucuromde an appropriately treated sample of patient semm mixed with an enzyme covalently labeled with 20HE1 , (b) incubating the mixmre from (a) for a period of incubation permitting competition between 20HE1- enzyme and serum 20HE1 -glucuronide fraction for binding to monoclonal antibody bound to the solid phase, (c) washing the plate, (d) adding to the washed plate a color-generating enzyme substrate to determine the amount of 20HE1- enzyme bound, (e) determinmg the quantity of 20HE1 -glucuronide fraction in each semm sample from the absorbance of the sample relative to a set of 20HE1 -glucuromde standards and controls of known concentration, and (0 comparmg the level of the 20HE1 -glucuronide fraction m the semm sample to an extrinsic numerical value derived either previously from me patient under testmg, or from the testmg of other subjects of the same species, to detect any differences m the level of the particular estrone metabolite and its glucuronide standards previously determmed to ascertain the presence of abnormal levels of 20HE1 -glucuronide fraction indicative of a pathology 16 The method of Claim 15 wherem the assay is buffered so as to be kept acidic to protonate said glucuromde fraction, thereby minimizing charge interactions with proteins m tissues and body fluids 17 The method of Claim 15 wherem the assay is performed at temperamres at or below 15 degress Centigrade 18 The method of Claim 15 wherein said pathology is breast cancer 19 The method of Claim 10 wherem said immunochemical analysis is a competitive enzyme-linked immunoassay (ELISA) usmg monoclonal antibodies and 2MeoEl -enzyme conjugates which comprises (a) adding to a microtiter plate coated with monoclonal antibody to 2MeoEl/2MeoEl-3-glucuronιde an appropriately treated sample of patient semm mixed with an enzyme covalently labeled with 2MeoEl , (b) incubating the mixmre from (a) for a period of incubation permitting competition between 2MeoE 1 - enzyme and semm 2MeoEl -glucuronide fraction for binding to monoclonal antibody bound to the solid phase, (c) washing the plate, (d) adding to the washed plate a color-generating enzyme substrate to determine the amount of 2MeoEl enzyme bound, (e) determining the quantity of 2MeoEl -glucuronide fraction m each semm sample from the absorbance of the sample relative to a set of 2MeoEl -glucuronide standards and controls of known concentration, and (0 comparing the level of the 2MeoEl -glucuronide fraction the semm sample to an extrinsic numerical value derived either previously from the patient under testing, or from the testing of other subjects of the same species, to detect any differences in the level of the particular estrone metabolite and its glucuronide standards previously determmed to ascertain the presence of abnormal levels of 2MeoEl -glucuronide fraction indicative of a pathology 20 The method of Claim 15 wherem the assay is buffered so as to be kept acidic to protonate said glucuronide fraction, thereby minimizing charge interactions with proteins in tissues and body fluids 21. The method of Claim 15 wherein the assay is performed at temperamres at or below 15 degrees Centigrade. 22. The method of Claim 15 wherein said pathology is breast cancer. 23. The method of Claim 1 wherein said level is measured in tissue. 24. The method of Claim 23 wherein said level is measured by immunohistochemical detection. 25. The method of Claim 24 wherein said immunohistochemical detection is by the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method. 26. The method of Claim 25 wherein me alkaline phosphatase-anti-alkaline phosphatase (APAAP) method comprises: (a) incubating fixed tissue sections mounted on glass slides sequentially with: 1) mouse monoclonal antibody to said 160HEl-glucuronide fraction; 2) rabbit polyclonal anti-mouse IgG antisemm, and 3) mouse anti-alkaline phosphatase: alkaline phosphatase immune complexes (APAAP) so that the rabbit anti-mouse IgG acts to bridge the primary monoclonal antibody the APAAP complex, linking the two together; (b) treating the tissue of step (a) with a color producing substrate for alkaline phosphatase to visualize the presence of tissue-bound APAAP, and hence tissue-bound antibody to said glucuronide fraction, by incubation of the treated tissue with a color producing substrate for alkaline phosphatase; and (c) observing the presence and location of color to indicate the presence and severity of the pathology. 27. The method of Claim 26 wherein the tissue sections are formalin-fixed paraffin-embedded tissue sections. 28. The method of Claim 26 wherein the coupling agent utilized is napthol AS-MX and the capture agent utilized is Fast Red, to afford a bright red color for indicating the presence of the glucuronide fraction. 29. The method of Claim 26 wherein the assay is buffered so as to be kept acidic to protonate said glucuronide fraction, thereby minimizing charge interactions with proteins in tissues and body fluids. 30. The method of Claim 26 wherein said pathology is breast cancer. 31 The method of Claim 25 wherem the alkaline phosphatase-anti-alkaline phosphatase (APAAP) method compnses (a) incubatmg fixed tissue sections mounted on glass slides sequentially wim 1) mouse monoclonal antibody to said 20HE1 -glucuromde fraction, 2) rabbit polyclonal anti-mouse IgG antisemm, and 3) mouse anti-alkaline phosphatase alkalme phosphatase immune complexes (APAAP) so that the rabbit anti-mouse IgG acts to bridge the primary monoclonal antibody the APAAP complex, linking the two together, (b) treating the tissue of step (a) with a color producmg substrate for alkaline phosphatase to visualize the presence of tissue-bound APAAP, and hence tissue-bound antibody to said glucuromde fraction, by mcubation of the treated tissue with a color producmg substrate for alkalme phosphatase, and (c) observing the presence and location of color to indicate the presence and seventy of the pathology 32 The method of Claim 31 wherem the tissue sections are formalin-fixed paraffin-embedded tissue sections 33 The method of Claim 31 wherem me coupling agent utilized is napdiol AS-MX and the capmre agent utilized is Fast Red, to afford a bright red color for indicating the presence of the glucuronide fraction 34 The method of Claim 31 wherem the assay is buffered so as to be kept acidic to protonate said glucuronide fraction, thereby minimizing charge interactions with protems in tissues and body fluids 35 The me od of Claim 31 wherem said pathology is breast cancer 36 The method of Claim 1 wherein said pathology is selected from neoplastic diseases such as endometrial cancer, breast cancer, cervical cancer, uterine cancer, ovaian cancer, prostate cancer, and combinations thereof 37 The method of Claim 36 wherem said pathology can be detected both pre- and post-operatively 38 The method of Claim 37 wherein said pathology is breast cancer 39 The method of Claim 38 wherein said detection can be used to determine the extent of lymph node involvement in breast cancer 40. The method of Claim 36 wherein said detection can be used to determine die reoccurrence of a neoplastic disease. 41. The method of Claim 36 wherein said detection can be used to determine the progression of the pathology and the response to therapy. 42. A test kit for the screening of a pathology wherein an alteration in estrogen metabolism is indicative of the pathology or a susceptibility thereto, using the semm, tissue or body fluid medium of a mammal under test, comprising: (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of one or more estrone metabolites and/or its 3-glucuronide fraction, or a specific binding partner thereto, to a detectable label; (b) other reagents as necessary to perform the assays according to this invention; and (c) directions for use of said kit. 43. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises antibodies to a 160HE1 -glucuronide fraction consisting of 160HE1 and 160HEl-3-glucuronide. 44. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises antibodies to a 20HE1 -glucuronide fraction consisting of 20HE1 and 20HEl-3-glucuronide. 45. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises antibodies to a 2MeoEl -glucuronide fraction consisting of 2MeoEl and 2MeoEl-3-glucuronide. 46. The test kit of Claim 42 wherein the label is an enzyme or an enzyme pair. 47. The test kit of Claim 46 wherein the label is selected from the group consisting of peroxidase, β- glucuronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose oxidase plus peroxidase, galactose oxidase plus peroxidase, hexokinase plus GPDase, glucose oxidase plus alkaline phosphatase, NAD oxidoreductase plus luciferase, phosphofructokinase plus phosphoenol pymvate carboxy lase, aspartate aminotransferase plus phosphoenol pymvate decarboxylase, and alkaline phosphatase. 48. The test kit of Claim 42 wherein the label is a chemical which fluoresces. 49. The test kit of Claim 48 wherein the chemical is selected from the group consisting of fluorescein, rhodamine, and auramine. 50. The test kit of Claim 42 wherein the label is a radioactive element. 51. The test kit of Claim 50 wherein the radioactive element is selected from the group consisting of C, ,25 I, I, 35 S, 57 Co, 59 Fe and 3 H. 52. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises the 160HE1 -glucuronide fraction consisting of 160HE1 and/or 160HEl-3-glucuronide. 53. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises the 20HE1 -glucuronide fraction consisting of 20HE1 and/or 20HEl-3-glucuronide. 54. The test kit of Claim 42 wherein the labeled immunochemically reactive component comprises the 2MeoEl -glucuronide fraction consisting of 2MeoEl and/or 2MeoEl-3-glucuronide

Inventors: KLUG THOMAS L, KLUG, THOMAS, L.
Applicants: IMMUNA CARE CORP, IMMUNA CARE CORPORATION
Application year: 1996
Main classification: G01N33
IPC codes: G01N33